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ABSTRACT 
The thesis focuses on the specific design of multifunctional magnetic nano-carriers for different 
biomedical areas. Different shapes of core/shell bi-magnetic nanoparticle have been synthesized by seed-
mediated growth, and their structural and magnetic properties have been studied. The experimental 
results showed that core/shell nanoparticles have a higher specific absorption rate compared to the core 
ones. For drug delivery application, the surface of the magnetic nanoparticles is functionalized using 
different techniques (Diels-Alder reaction and layer-by-layer technique). 
More precisely, a novel bi-functional thermo-responsive system, which consists of core/shell bi-magnetic 
nanoparticles with furan surface functionality, is bonded with N-(2-Carboxyethyl)maleimide through 
Diels-Alder reaction. The chemotherapeutics doxorubicin is attached onto the surface of the nano-
carriers, and a high loading efficiency of 92% is obtained. This system with high responsiveness to a high 
frequency external alternating magnetic field shows a very good therapeutic efficiency in hyperthermia 
and drug release at relatively low temperatures (50 °C). On the other hand, a switch-controlled drug 
release is realized by coating the core/shell bi-magnetic nanoparticle with a pH- and thermo-responsive 
polymer shell. Doxorubicin is loaded onto the surface of the last coating layer, and a high loading efficiency 
is obtained. The nano-carriers are characterized with FTIR, dynamic light scattering, Zeta potential, In vitro 
hyperthermia, and vibrating sample magnetometry. The in vitro drug release experiments confirm that a 
small amount of doxorubicin is released at body temperature and physiological pH, whereas a high drug 
release is obtained at acidic tumor pH under hyperthermia conditions (43 °C). The core/shell bi-magnetic 
nano-carriers facilitate controllable release of doxorubicin as effect of induced thermo- and pH-
responsiveness of the polymer when are subjected to an high-frequency alternating magnetic field at 
acidic pH; thereby the drug release rate is controlled using on-off cycles of the applied field. 
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KURZFASSUNG 
Diese Arbeit befasst sich mit der speziellen Gestaltung von multifunktionalen magnetischen 
Nanopartikeln für diverse biomedizinische Anwendungen. Verschiedene Formen der Kern/Schale-bi-
magnetischen Nanopartikel wurden durch die „seed-mediated growth“ Methode synthetisiert, und die 
strukturellen und magnetischen Eigenschaften dieser Formen untersucht. Die Versuchsergebnisse haben 
gezeigt, dass die Kern/Schale-Nanopartikel eine höhere spezifische Energiea als reine Kern Partikel haben. 
Für die Drug Delivery Anwendung wird die Oberfläche der magnetischen Nanopartikel auf 
unterschiedlichen Wege (Diels-Alder-Reaktion und Layer-by-Layer-Verfahren) funktionalisiert.  
Dazu wurde an ein neuartiges bifunktionelles thermosensitives System, welches aus furanbeschichteten 
Kern/Schale bi-magnetischen Nanopartikel besteht, N-(2-Carboxyethyl) maleimid durch Diels-Alder 
Reaktion angebunden. Mit der Anbindung des chemotherapeutischen Doxorubicins an die Oberfläche der 
nano-carriers wurde ein hohe Beladungsgrad von 92% erzielt. Dieses System mit hoher 
Ansprechempfindlichkeit auf hochfrequente äußere magnetische Wechselfelder zeigt eine sehr gute 
therapeutische Wirksamkeit in der Hyperthermie und als Drug-Delivery-System bei relativ niedrigen 
Temperaturen (50 °C). Ein schaltbare Wirkstofffreisetzung wird durch Beschichtung der Kern/Schale 
bimagnetischen Nanopartikel mit einer pH- und temperaturempfindlichen Polymerschicht ermöglicht. 
Mit der Anbringung des Doxorubicins auf die Oberfläche der letzten Beschichtung wurde eine hohe 
Beladungseffizienz erhalten. Diese System wird mittels dynamischer Lichtstreuung, FT-IR-, In-vitro-
Hyperthermie, UV/Vis- und Fluoreszenz-Spektroskopie, sowie Zetapotential-Messungen charakterisiert. 
Die in vitro Wirkstofffreisetzungsversuche bestätigen, dass eine kleine Menge von Doxorubicin bei 
Raumtemperatur und physiologischen pH freigesetzt wird, während eine hohe Wirkstofffreisetzung bei 
sauren pH-Werten in Tumoren unter Hyperthermi Bedingungen (43 ° C) erhalten wird. Die Kern/Schale bi-
magnetischen Nanopartikel erleichtern die Freisetzung von Doxorubicin infolge der induzierten thermo- 
und pH-Ansprechempfindlichkeit des Polymers, wenn sie in einem hochfrequenten magnetischen 
Wechselfeld einem sauren pH-Wert ausgesetzt werden. Dadurch wird die Arzneimittelfreisetzungsrate 
anhand on-off -Zyklen des angelegten Feldes gesteuert. 
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1 INTRODUCTION 
Healthcare and life science applications have drawn a great deal of interest for nanotechnology based 
systems and solutions. Nanostructured drugs and targeted drug delivery, sensing of target molecules, and 
imaging of cell and tissues are just a few examples for applications in medicine. However a wide variety 
of materials are used in medicine, the magnetic nanoparticles (MNPs) seem to hold one of the fastest 
moving and most exciting research areas. MNPs have a diverse range of applications from engineering to 
biomedical aspects. In fact, the application of MNPs to target tumor cells inside the human body was first 
conceived in the late 1970’s.[1,2] The key point was to inject the attached anticancer drugs to small 
magnetic spheres inside the body and concentrate the drug-loaded particles inside the tumor tissue under 
applying external magnetic fields (AMF), in order to reduce drug payload, and thereby reduce the side 
effects associated with chemotherapeutic agents.  
The present dissertation is an attempt to solve some of today’s most important problems that drive to 
the side effect of chemotherapy and extend the hyperthermic effect of the MNPs with novel design and 
functionality of MNPs. In principle, this doctorate thesis is divided into five parts. In the first part 
concerning synthesis of shape-anisotropic and core/shell magnetic nanoparticles (CS-MNPs), physical 
properties, and surface modification for hyperthermia application are reviewed. The study presents the 
effects of substitution of Zn2+ on the structural and magnetic properties of ZnxCo1-xFe2O4@MnFe2O4 
nanoparticles, which affect the specific absorption rate (SAR), and thus may extend hyperthermia therapy 
to deeper tumors. 
Part 2 focuses on the control and characterization of magnetic properties of the 
Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 nanoparticles, which enhanced the SAR of bi-magnetic nanoparticles. 
This research has been focused on chemical synthesis of truncated octahedron CS-MNPs in order to 
improve their SAR, which can suppress the amount of injected CS-MNPs in cancer therapy and heat shock 
protein because of improved heating efficiency of CS-MNPs. The study demonstrates that the SAR could 
be tuned by the concentration of precursor and the synthesis time, and reveals the relationship between 
the heating performance and the magnetic properties at high frequency.  
In part 3 we develop a facile method which is based on functionalized CS-MNPs, which consists of shape-
anisotropic CS-MNPs, functionalized with doxorubicin (DOX) via a thermo-responsive linker, and 
demonstrate a controlled drug release system upon exposure to high-frequency alternating magnetic field 
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(HF-AMF) radiation based on the retro-Diels/Alder (rDA) reaction. A fast drug release is activated by rDA 
reaction and could be applied synergistically with hyperthermia. 
Alternatively in part 4 we use the layer-by-layer (LBL) technique to develop a dual pH- and thermo-
responsive MNPs drug carrier which is suitable for the magneto-thermal therapy and controlled release. 
Poly(allylamine-hydrochloride) (PAH) and polyacrylic acid (PAA), biodegradable polyelectrolytes, will be 
used as functionalization agents of CS-MNPs and as external stimulus-responsive polymers. The system 
provides an improved controlled release of the anticancer drug over burst release when is subjected to 
HF-AMF and tumor acidic pH. 
Finally, Part 5 summarizes the results of this doctorate work and gives conclusions of the work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
2 THEORY AND BACKGROUND 
2.1 MAGNETIC NANOPARTICLES 
2.1.1 Introduction 
In recent years, much attention has been paid to the development of MNPs, the understanding of their 
behavior, and the successful application of such MNPs in the life science areas.[3] MNPs with relevant 
physiochemical and structural properties have been extensively investigated for various applications such 
as magnetic drug targeting, hyperthermia, magnetic resonance imaging (MRI), tissue engineering and 
repair, biosensing, biochemical separations, and bioanalysis.[4] The preparation of monodisperse-sized 
nanoparticles is very important because the physicochemical properties of these nanoparticles depend 
strongly on their dimensions. For biomedical uses, MNPs should possess very small size and narrow size 
distribution together with high magnetization values. The major advantage of using small size particles is 
their higher effective surface areas, lower sedimentation rates, and improved tissular diffusion.[5] Finally, 
we address some of the most relevant preparation effects on the magnetic properties and structure of 
the MNPs. 
2.1.2 Synthesis of Magnetic Nanoparticles 
During the last few years, great interest has been recently devoted to the development of shape-
controlled, highly stable, and narrow size distribution MNPs with enhanced magnetic properties. 
The main synthesis pathways for the preparation of MNPs are reported as follows:[6] 
1) Physical methods, such as gas-phase deposition and electron beam lithography.  
2) Wet chemical preparation methods, such as sol–gel synthesis, oxidation method, chemical co-
precipitation, hydrothermal reactions, flow injection synthesis, thermal decomposition, aerosol/vapor-
phase method, supercritical fluid method, and synthesis using nanoreactors. 
3) Microbial methods, which are generally simple, efficient, versatile. 
The overview focuses on thermal decomposition and co-precipitation method because it is relevant with 
our synthesis of magnetic nanoparticles. 
2.1.2.1 Thermal decomposition 
Monodisperse MNPs with smaller size can be synthesized through the thermal decomposition of 
organometallic compounds in high-boiling organic solvents containing stabilizing surfactants. The key 
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factor for the production of monodisperse MNPs can easily be obtained by controlling the ratios of the 
starting reagents including organometallic compounds, surfactant, and solvent reaction, as well as the 
experiment parameters such as temperature, heating time, and heating rate.[7] Narrow size distribution 
and shape control of magnetic nanoparticles can be obtained due to feature of the nucleation and growth 
mechanisms during the decomposition of the precursors.[8] 
A large number of nuclei are formed by the formation of molecular clusters as monomers which are 
obtained by degradation of the precursor molecules. When the temperature increases, the concentration 
of these clusters increases until it reaches a critical point of supersaturation. The particles grow at the 
same rate, once the reaction mixture has reached a growth temperature leading to a homogeneous size 
distribution.[9] Particle growth can be stopped by removing the temperature source.  
A burst nucleation can basically be initiated in two ways: when the monomers quickly rise over critical 
supersaturation, a burst nucleation occurs and thus grow at the same rate, forming monodisperse 
particles,[10] or by rapid injection of reagents into the reaction (figure 2.1). 
 
 
Figure 2.1. a) Schematic illustration of the LaMer model, b) a typical “hot-injection” set-up to achieve the burst 
nucleation. Reprinted from ref. 10. 
 
Decomposition of nonmetal precursors such as carbonyl leads to formation of the metal nanoparticles. 
For instance, Hyeon et al. were able to prepare monodisperse γ-Fe2O3 nanocrystals with a size of 
approximately 13 nm by decomposition of iron pentacarbonyl at 100 °C and subsequent addition of 
trimethylamine oxide as a mild oxidant at elevated temperature.[11] The thermal decomposition of iron 
pentacarbonyl at relatively low temperature lead to nucleation, and the decomposition of the iron oleate 
complex at a higher temperature induces growth. Peng et al. reported the synthesis of size- and shape-
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controlled magnetic oxide nanocrystals based on the pyrolysis of metal fatty acid salts in non-aqueous 
solution.[12] The size of the particles could be controlled from 3-50 nm by adjusting the 
precursor/surfactant ratio, the temperature, and the injection time as shown in figure 2.2. 
 
 
Figure 2.2. TEM images of Fe3O4 nanocrystals taken at different reaction times. Reprinted from ref. 12. 
 
The thermal-decomposition method is also used for preparation of metallic nanoparticles, which have 
high magnetization compared to metal oxides. Metallic iron nanoparticles were synthesized by thermal 
decomposition of Fe(CO)5 in the presence of polyisobutene in decalin under nitrogen atmosphere at 170 
°C.[13] 
2.1.2.2 Co-precipitation method 
The co-precipitation method is considered as the convenient chemical way to synthesize iron oxide 
nanoparticles from aqueous Fe2+/Fe3+ salt solutions by the addition of a base under inert atmosphere at 
room temperature or at elevated temperature. The MNPs prepared at or near room temperature, are 
usually poorly crystalline, or amorphous. On the other hand, when the co-precipitation reaction occur at 
higher temperatures (50-100 °C), it leads to condensation of the precipitated metal hydroxides to form 
crystalline metal oxides.[14] 
 
Figure 2.3. TEM image of Zn0.4Co0.6Fe2O4 synthesized by co-precipitation method. 
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Depending on the type of salts (e.g. chlorides, sulfates, nitrates), the Fe2+/Fe3+ ratio, the reaction 
temperature, the pH value, and ionic strength of the media, MNPs can be produced in a highly 
reproducible fashion. Since the magnetite  is  sensitive  to  oxidation,  an  inert  gas  purging  is  needed  
during the reaction to prevent magnetite transformation to maghemite. The disadvantage of co-
precipitation method is controlling of the particle size and thus obtaining a narrow particle size 
distribution. A dispersibility of nanoparticle in water can be improved by subsequent acidification of the 
particle surface with nitric acid or by addition of tartrate ions, giving the MNPs stability in acidic and basic 
media over long periods of time.[15] The main advantages of this method are the high reproducibility and 
high yields which are especially interesting for industrial scale applications.[16] 
2.1.3 Nanomagnetism 
2.1.3.1 Introduction 
Nanomagnetism concerns the characteristic length scale of magnetism, which deals with the magnetic 
properties of objects that have at least one dimension in the nanoscopic range. The local atomic symmetry 
results from the crystal structure and finite-size effects due to quantum confinement of the electrons 
inside the material dominate the behaviour of these structures and are responsible for these unique 
properties.[17] Because of their extraordinary magnetic properties, nano-magnets have many applications 
in life science which is different from the bulk magnets, such as magnetic recording, giant 
magnetoresistance (GMR) devices, targeting drug delivery, MRI, magnetic hyperthermia, and 
bionsensors.[18] We will introduced briefly the important nanomagnetic effects, and then discuss the 
magnetic loss processes. 
2.1.3.2 Single domain and superparamagnetism 
The subdivision of MNPs according to finite-size effects are classified by: (1) The single domain limit and 
(2) the superparamagnetic limit, which both lead to individual material-dependent length scales. The size 
of the magnet has a great influence on its magnetic behavior. As the size of magnet increase, the number 
of domains will increase, and thus the magnetostatic energy will decrease, whereas the more domain 
walls will also increase the exchange and the anisotropy energies. Also the size of the magnet affect the 
coerecivity.[19] As shown in figure 2.4, for very small particles whose diameters are below than the critical  
diameter  of  superparamagnetism  (Dspm),  the  magnetic  moment  is  not  stable,  and therefore coercivity 
(Hc) is 0.  However, the moment is stable in the range between Dspm and the critical diameter of a single 
domain (Dsd). Finally, for the multi-domain region, Hc decreases with increasing particle diameter.  
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Therefore, the magnetic nanoparticle has the maximal Hc when its diameter is equal to Dsd, and it will 
become superparamagnetic when its diameter becomes smaller than Dspm.[20] 
. 
 
Figure 2.4. Size dependence of coercivity of magnets. 
 
All the magnetic moments for the single domain magnet are aligned to the anisotropy axis, thus the 
exchange energy and anisotropy energy is zero. Therefore, the magnetostatic energy is the only dominant 
energy. The reason for such an arrangement arises from the fact that the thermal energy in smaller 
particles will be able to overcome the anisotropy energy. So the magnetization is no longer in a stable 
configuration. Nanoparticles with an uniaxial anisotropy randomly flip the direction of their 
magnetization. This effect is induced by thermal energy. The average time to perform such a flip is given 
by the relaxation time:[21] 
 
𝜏𝑁 =  𝜏0 exp (
𝐾𝑉
𝑘𝐵𝑇
)                     (2.1) 
Where: 
 
τN is the average length of time that it takes for the nanoparticle’s magnetization to randomly flip as a 
result of thermal fluctuations, τ0 is a length of time, characteristic of the material, called the attempt time 
or attempt period; its typical value is 10−9 – 10−10 second, K is the nanoparticle’s magnetic anisotropy 
energy density and V its volume. KV is therefore the energy barrier associated with the magnetization 
moving from its initial easy axis direction, through a “hard plane”, to the other easy axis direction, kB is 
the Boltzmann constant, and T is the temperature. 
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The KV is usually much higher than the thermal energy kBT, however, with decreasing of particle size, KV 
decreases to values below kBT. As a result, the magnetic moments are able to overcome the energy barrier 
and freely flip in any direction, this phenomenon is called superparamagnetism.  
Another factor in observing superparamagnetism is the measurement time (τm). When the τm is much less 
than the Neel relaxation time (τm< τN), a blocked state occurs because there is no direction flip. In this 
state, the nanomaterials behave like a normal paramagnet but with a much higher susceptibility. When 
the τm is much greater than the Neel relaxation time (τm> τN), this results in the superparamagnetic state 
in which the net moment is zero due to the fluctuations in magnetization.[22] The blocking temperature 
(TB) is the temperature between the blocked and superparamagnetic states, or the temperature at which 
τm = τN. It can be calculated by the following equation:     
 
        𝑇𝐵 =  
∆𝐸
𝐾𝐵 ln(
𝑇𝑚
𝑇0
)
                                                          (2.2) 
 
2.1.3.3 Exchange-coupling effect 
Kneller and Hawig in 1991 proposed that the exchange spring magnet utilizes the epitaxy between hard 
and soft magnetic materials. Therefore the hard material helps retain the soft material’s anisotropy, which 
increases its Hc (figure 2.5).[23] The exchange-coupling effect only takes place at the interphase boundary 
between hard and soft magnets at nanoscale. Such magnets are referred to as `exchange-spring’ or 
`exchange-hardened’ magnets and its high magnetization improved the energy product (BH)max .The hard 
phase enhances the magnetic anisotropy and stabilizes the exchange-coupled soft phase against 
demagnetization. For an efficient exchange coupling, the thickness of the soft phase cannot exceed about 
twice the wall thickness of magnetic domains in the hard phase, which typically limits the size of the soft 
grains to ∼10 nm, and the volume fraction of the soft phase must not be too high in order to lose a large 
Hc value, which limits the (BH)max of the composite.[24] 
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Figure 2.5. Typical hysteresis loops: (i) a hard phase, (ii) a soft phase and (iii) the exchange-coupled 
nanocomposites made of the soft and hard phases. 
2.1.3.4 Exchange bias effect 
CS-MNPs have recently received considerable attention owing to their physical and chemical properties 
that are strongly dependent on the structure in which the magnetic core is coated with a layer of 
antiferromagnetic (AFM) or ferro/ferromagnetic (FM) shell. In these systems the exchange interaction 
between hard and soft constituents leads to exchange bias,[25] and improvements in the thermal stability 
of the core.[26] These materials can exhibit desirable properties, i.e. high saturation magnetization (Ms)and 
high SAR arising from the hard and soft phases, respectively.[27] The magnetization of small size 
nanoparticles increases and the coercive field  monotonically decreases as the soft-phase shell thickness 
is increased.[28] Moreover reversal of the FM moment will have an added energetic cost corresponding to 
the energy necessary to create a Néel domain wall within the AFM film, and thus implies a shift in the 
switching field of the FM (figure 2.6). The Curie temperature (Tc) of the FM in the FM/AFM bilayers is 
larger than the Néel temperature (TN) of the AFM. 
 
 
Figure 2.6. Above the TN of the AFM all its spins are disordered. Below TN they become ordered and the exchange 
coupling between FM and AFM spins leads to the shift of the hysteresis loop. 
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2.1.3.5 Magnetic loss process 
Magnetic losses to be utilized for heating arise due to different processes of magnetization reversal in 
systems of magnetic nanoparticles which depend in different manners on the applied magnetic AC field 
amplitude and frequency. Moreover, there is a strong dependence of magnetic particle properties on 
structural ones like mean size, size distribution, particle shape and crystallinity. High-frequency magnetic 
fields may cause heating in magnetic materials due to different processes of magnetization reversal in the 
particle system: hysteresis loss, and Brownian and Néel relaxation. 
Hysteresis loss is due to the reversal of magnetization of transformer core whenever it is subjected to 
alternating nature of magnetizing force .Whenever the core is subjected to an AMF, the domain will 
change their orientation after every half cycle. The power consumed by the magnetic domains for 
changing the orientation after every half cycle is called hysteresis loss. The hysteresis loss occur in 
magnetic particles on the order of 100 nm or larger.[29] Hysteresis remains significant in larger single-
domain particles as well; however, both Hc and remanence magnetization (Mr) depend strongly on particle 
volume and both decrease for smaller particles.[30] This dominance occurs when the relaxation time of the 
particle is equal to the field frequency. 
With decreasing particle size, the energy barrier for magnetization reversal decrease, and consequently 
thermal fluctuations lead to relaxation phenomena. When the particle rotates itself, the particle has 
undergone Brownian relaxation and thermal energy is delivered through shear stress in the surrounding 
fluid. On other hand, if the moment rotates while the particle itself remains fixed, the particle has 
undergone Néel relaxation and thermal energy is dissipated by the rearrangement of atomic dipole 
moments within the crystal (Figure 2.7).[31] 
 
Figure 2.7. a) Néel rotation, B) Brownian rotation reprinted from ref 31. 
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 In the absence of a field, the crystalline anisotropy of the particle affect the orientation of this moment. 
However, the energy produced from AMF tends to displace the moment from the preferred orientation 
and relaxation of the moment reverse to equilibrium releases thermal energy, which results in local 
heating. In the case of a Néel relaxation mechanism, the physical orientation of the particle remains 
unchanged while the moment alternates between parallel and antiparallel orientations (equation 2.1).[32] 
Heating occurs in Brownian mechanism via shear in the surrounding carrier fluid. When  the magnetic 
anisotropy of the particle overcome the inertial or viscous resistance, an AMF may cause rotation of the 
particle in the fluid, while the magnetic moment remains fixed relative to the crystal axis. The viscosity of 
the solution η and the hydrodynamic volume of the particle VH affect strongly the Brownian relaxation 
time, and is given by the following:[33] 
 
                                 𝜏𝐵 =  
3𝜂 𝑉𝐻
𝐾𝑇
                                                                         (2.3) 
 
Néel and Brownian mechanisms occur in parallel, and so the effective relaxation time of the system is 
given by 
                                                                               
1
 𝜏
=  
1
𝜏𝐵
+  
1
𝜏𝑁
                                                                      (2.4) 
 
Here it is clear that the effective relaxation time is dominated by the shorter of the two components. Thus 
Brownian relaxation tends to dominate at larger particle volumes and lower viscosities, and Néel for small 
particles in viscous solutions. In magnetic fluids, heating effects can be achieved in AC magnetic fields by 
Néel type relaxation losses or energy dissipation during particle rotation in liquid (Brown losses). 
2.1.4 Application in life science 
2.1.4.1 Drug delivery system 
One of the most attractive applications for MNPs is targeted drug delivery. It is a challenge to deliver the 
drug to the target organ inside the body because of the circulation system and clearance system of body. 
Transportation of drugs to a specific site can eliminate side effects and also reduce the dosage required. 
Where nanoparticles are functionalized with appropriate groups loaded with drugs and directed to and 
focused at tumor sites by an AMF. The size, surface chemistry, and charge are particularly important for 
bioavailability of the drug. It is desirable that the size of MNPs is ranging from 10 to 100 nm for drug 
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delivery applications. A gradient magnetic field needs to be placed in terms of direction and strength of 
the particle. Particles will move under applied magnetic field. The force felt by a nanoparticle is given by  
 
          𝐹 = (𝑚 ∗ ∇) 𝐵                                                               (2.5) 
 
where B is the applied field and m is the magnetic moment of the particle. The process of drug localization 
using magnetic delivery systems is based on the competition between the forces exerted on the particles 
by the blood compartment and the magnetic forces generated from the magnet. 
Zimmermann and Pilwat  used magnetic erythrocytes for the delivery of a cytotoxic drug, methotrexate.[34] 
In the 1980s, many authors developed delivery strategies for various drugs using microcapsules and 
microspheres.[35] 
2.1.4.2 Hyperthermia 
Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperature. It is 
based on the fact that cells show signs of apoptosis when heated in the range of 41 °C to 47 °C and necrosis 
when heated to above 50 °C.[36] By killing cancer cells and damaging proteins and structures within cells, 
hyperthermia may shrink tumors. 
The advantage of magnetic hyperthermia is: (a) it provides a non-invasive way to raise cell temperatures 
to a therapeutic level; (b) MNPs can be visualized using MRI; and (c) the particles can also be functionalized 
and combined with other types of treatment such as chemotherapy or radiotherapy. Maier-Hauff et al. 
studied a clinical breakthrough of therapeutic hyperthermia induced by heating implanted MNPs (figure 
2.8).[37] Moreover, the use of nanometer-sized MNPs is much more than micron-sized particles in 
hyperthermia due to the fact that the smaller nanoparticle will absorb more power at AC magnetic field.[38]  
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Figure 2.8. Three-dimensional reconstruction image (MagForce NanoPlan_ software) of a skull with a frontal 
glioblastoma multiforme after magnetic resonance imaging and computed tomography. A calculated 42 °C 
treatment isotherm surface (transparently red) enclosing. 
 
2.1.4.3 MRI Contrast Agents 
For many years, superparamagnetic nanoparticles have been used as contrast agent mainly for diagnosis 
of soft tissue or cartilage pathologies in MRI and magnetic resonance angiography (MRA). This is because 
of their T2* (T = transverse relaxation) property with high sensitivity in T2* and T2 weighted images, when 
compared to other MRI agents.[39] The T2-relaxation effects result in a signal reduction on T2-weighted 
images, thus providing a dark or negative contrast due to the induction of strong magnetic susceptibility 
on the water protons around the particles.[40] The magnetic fluids should be dispersed into a 
biocompatible and biodegradable carrier. In the liver, MNPs more than 50 nm in size are rapidly taken by 
hepatic and splenic macrophages, resulting in hypointense T2-weighted images of the normal tissue.[41] 
The lack of Küpffer cells in the tumor helps to differentiate between healthy and malignant regions. On 
other hand, very small MNPs avoid high uptake by liver and spleen macrophages and thus exhibit long 
circulating time, and it can be transported to the pathological tissues by endocytosis , transcytosis, and by 
direct passage through the inflammatory leaky vasculature.[42] As shown in Figure 2.9a-c, the tumor 
treated with the MnFe2O4–Herceptin NPs shows color changes from red to blue in the color-coded MR 
images.[43] In contrast, those treated with the Fe3O4–Herceptin NPs have no apparent change in the color-
coded MR images (Figure 2.9d–f), indicating the higher MRI sensitivity can be obtained by using high 
moment superparamagnetic nanoparticles. 
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Figure 2.9. a–c) Color maps of T2-weighted MR images of a mouse implanted with the cancer cell line NIH3T6.7 at 
different time points after injection of MnFe2O4–Herceptin and d–f)  Fe3O4–Herceptin conjugates. Reprinted from 
ref 43. 
 
2.1.4.4 Bioseparation 
Biomagnetic separation techniques are becoming most recently developed revolutionary technology in 
bioscience research. Magnetic micro- or nanospheres can be separated easily by an AMF and can be 
bonded with appropriate ligands, such as antibodies or proteins, with a high affinity to the target cells, 
bacteria or DNA/RNA. Biomagnetic separation is ideal for automated assay and analysis systems because 
of its advantages which are fast, reliable sample handling and can be used for large sample volumes 
without time-consuming centrifugation steps. Superparamagnetic iron oxide particles have been 
extensively used for separation and purification of cells and biomolecules in bioprocesses.[44] 
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2.2 DIELS–ALDER REACTION 
2.2.1 Introduction 
Remote control of the rate of drug release by using an AMF is a persistent challenge in medicine. 
Controlled release formulations of therapeutic molecules from a magnetic platform offer several 
advantages, such as delivery of the desirable amount of the drug to the target of interest and synergistic 
effects of hyperthermia to the affected tissue. In order to provide on-demand drug release it is necessary 
to have a switching material that can modulate the drug release kinetics upon an external triggering 
electromagnetic field.  Click reactions have the potential to greatly facilitate the development of 
controlled drug delivery systems and biomaterials. The Diels–Alder (DA) cycloaddition is one of the click 
reactions that are used in synthetic organic chemistry and material design which do not need any metal 
catalyst. The DA reaction is efficient in the absence of catalysts, even though the reaction rate can then 
be slow at room temperature. Thermally rDA between various furan and maleimide derivatives have 
attracted particular attention because they can occur under mild conditions with high chemo-
selectivity.[45] The DA reaction is stereoselective, atom economical, and highly efficient; it is one of the 
most powerful methods to synthesize unsaturated six-membered rings.[46] 
2.2.2 Reaction mechanism 
The DA reaction is known as a thermo-reversible reaction between diene and alkene derivatives 
(dienophiles) to form cyclic hydrocarbon chains in aqueous conditions (figure 2.10a).[47] The 
intramolecular DA cycloaddition occurs if both the diene and the dienophile are part of the same molecule 
(Figure 2.10B). Moreover, if at least one heteroatom is involved in the reaction, the reaction called hetero-
DA reactions (Figure  2.10C).[48] In contrast of the normal electron-demand DA reaction, for which the 
reaction occurs between  electron-rich dienes and electron-poor dienophiles, an alternative reaction, in 
which a six-membered ring is formed between an electron-poor diene and an electron-rich dienophile 
(Figure 2.10D).[49] Therefore,  reactive dienophiles are substituted with electron withdrawing groups, such 
as carbonyls, ketones, carboxyls, nitriles or halogens, while dienes are substituted with electron donating 
groups, such as alkyl chains. 
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Figure 2.10. a) Normal electron-demand DA reaction, b) intramolecular DA reaction , c) hetero-DA reaction, and d) 
inverse electron-demand DA reaction. Reprinted from ref 48 
The speed and reversibility of the DA reaction is dependent on the temperature. At low temperatures the 
DA adduct is dominant and the cross-linked networks are relatively stable.  The unfavorable electron 
distribution within the reaction partners will slow the reaction. The cycloaddition reaction will be faster if 
the electron-poor dienophiles are reacted with electron-rich dienes (normal electron-demand DA 
reaction). 
2.2.3 Synthetic application 
DA reaction have attracted particular attention in pharmaceutical or biomedical aspect. Furan and 
maleimide pairs is the most reactant used in the reaction because of high availability, and can be easily 
functionalized with the reactive moieties under mild conditions with high chemo-selectivity. Also, it is 
advantageous that the DA reaction readily proceeds in water which is not toxic and cheap. Furthermore 
the reaction is accelerated in water due to enhanced hydrogen bonding to the activated complex and 
hydrophobic interactions between the reactants.[50] Moreover, there is no by-product formed because of 
the absence of catalyst, so the purity of the product will be high. This is especially important if 
macromolecules, such as polymers, dendrimers, proteins or nucleic acids, are involved in the reaction. 
The DA cycloaddition/cycloreversion reaction can be used to protect or deprotect functional groups, 
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preparation of degradable or self-healing materials, and in the design of controlled drug delivery systems. 
For instance, Woodward et al. used a Diels–Alder reaction to synthesize cortisone and cholesterol. Also 
the DA reaction has been utilized for the synthesis of dendrimers. The coupling between furan and 
maleimide was utilized to assemble symmetrical, thermally responsive dendrimers. On the other hand, it 
is used in the fabrication of surfaces that interact with cells. For example, de Araújo et al. applied DA 
reaction for the immobilization of streptavidin–diene conjugates on maleimide-functionalized glass 
surfaces.[51] Moreover the reaction is suitable for the preparation of hydrogels which can be used as space 
filling agents, vehicles for the delivery of drug, and scaffolds for cell delivery. For instance,  Nimmo et al. 
produced a new type of vehicles for drug targeting which is  furan-modified hyaluronic acid derivatives 
cross-linked with maleimide-functionalized PEG.[52] 
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2.3 LAYER-BY-LAYER ASSEMBLY 
2.3.1 Introduction 
For magnetic targeted drug delivery, the MNPs should possess small sizes, narrow size distributions, and 
high SAR values. In in vivo applications, MNPs have a higher tendency to agglomerate because of their 
inherent cohesion due to magnetic interactions.[53] The agglomeration leads to a reduction of the 
circulation time of magnetic nanoparticles in the bloodstream.[54] To overcome this challenge, the 
magnetic nanoparticles are coated by polyelectrolyte LBL technique in an attempt to tune physical and 
chemical properties. The key advantage of the LBL method is the simplicity, versatility, flexibility, and 
biocompatibility.[55] An increase in the shell thickness significantly reduces the polydispersity of the whole 
particle system, and increases the predominant repulsive interaction due to surface charges at the outside 
of the shell.[56] The LBL assembly technique was first developed and introduced in 1966 by Ilerat Dupont.[57] 
The technique did not receive much credit nor attention from the scientific community until it was 
pioneered in 1991 by Decher et al. as a solution for deposition of charged polymers.[58] 
2.3.2 Assembly Concept 
LBL assembly consists of the sequential adsorption of complementary multivalent molecules on a surface, 
occurring either via electrostatic or nonelectrostatic interactions (Figure 2.11). The LBL buildup of 
multilayer assemblies generally can be performed through a variety of deposition methods including dip-
coating, spin-coating, spraying, and perfusion. The electrostatic interaction is one of the most important 
among the interactions between molecules and surfaces when both molecule and adsorbent surface are 
electrically charged. As a result of electrostatic interactions, we can obtain multilayer films with well-
controlled composition, structure, and thickness by simply repeating the coating. 
 
Figure 2.11. Schematic representation of the buildup of multilayer thin films via electrostatic interaction 
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The architecture and properties of the films deposited by this method (such as thickness, chemical 
composition, structure, roughness, wettability, and swelling/shrinking behavior) can be well-controlled by 
varying the properties of the adsorbed species such as the charge density, composition, and structure. 
The physicochemical properties of the liquid medium such as the salt/buffer composition, solvent quality, 
ionic strength, and pH also can play a role in the determination of the thickness of the layer. Moreover 
the external parameters such as temperature, exposure to light, mechanical stress, electrical field, 
adsorption time, and number of layers deposited during the assembly process affect the coating.[59] 
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3 EXPERIMENTAL SECTION 
3.1 PART I 
The CS-MNPs were synthesized by the seed-mediated growth method.[60] In the first step we synthesized 
ZnxCo1-xFe2O4 nanoparticles with x varying between 0 and 0.8 as seed nanoparticles. Secondly, a MnFe2O4 
shell was over-grown by thermal decomposition onto the surface of the seed particle.                         
3.1.1 Synthesis of ZnxCo1-xFe2O4 nanoparticle seeds 
Zn(acac)2 (x mmol) , Co(acac)2 (1-x mmol), and Fe(acac)3 (2 mmol) were placed in a (50 mL) three-neck 
round-bottom in the presence of oleic acid (6 mmol), oleylamine (6 mmol), and benzyl ether (20 mL). The 
mixture was heated to reflux for 60 min at 300 °C, with a heating rate of 8 °C/min, under an argon 
atmosphere and cooled down to room temperature. Under ambient conditions, ethanol was added to the 
mixture resulting in black precipitate via centrifugation (4500 rpm, 10 min). The black powder was 
dissolved in hexane. 
3.1.2 Synthesis of ZnxCo1-xFe2O4@MnFe2O4 nanoparticles  
Mn(acac)2 (1 mmol), and Fe(acac)3 (2 mmol) were placed in a (50 mL) three-neck round-bottom in the 
presence of oleic acid (6 mmol), oleylamine (6 mmol), and benzyl ether (20 mL). After the addition of the 
ZnxCo1-xFe2O4 nanoparticles suspended in hexane, the mixture was first heated to 100 °C for 30 min to 
remove the hexane, and then heated to reflux 300 °C for 30 min under an argon atmosphere with a 
heating rate of 8 °C/min. After cooling, the ethanol was added to the mixture resulting in black precipitate. 
The obtained precipitate was dispersed in toluene after centrifugation. 
3.1.3 Preparation of hydrophilic ZnxCo1-xFe2O4@MnFe2O4 Nanoparticles 
CS-MNPs were transferred from toluene to the aqueous phase by surface modification using TMAOH.[61] 
The nanoparticles were precipitated and centrifuged, and subsequently TMAOH/butanol (1M) solution 
was added. The mixture was allowed to react for 30 min under sonication. After the mixture was 
centrifuged, supernatant was removed and the black precipitate was washed with excess amount of 
hexane. The nanoparticles were dispersed in water. 
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3.2 PART II 
The CS-MNPs (Zn0.4Co0.6Fe2O4@xZn0.4Mn0.6Fe2O4) have been synthesized by the seed-mediated growth 
method, where x is the molar concentration of precursor (x=1 and x=0.5, respectively), and y is the 
synthesis time (y=30 and y=60 min, respectively). Zn0.4Co0.6Fe2O4 nanoparticles were used as seeds and 
Zn0.4Mn0.6Fe2O4 particles were over-grown by thermal decomposition onto the surface of the seed 
particle.  
3.2.1 Synthesis of Zn0.4Co0.6Fe2O4 nanoparticle seeds 
Zn(acac)2 (0.4 mmol) , Co(acac)2 (0.6 mmol), and Fe(acac)3 (2 mmol) were placed in a 50 mL three-neck 
round-bottom in the presence of oleic acid (6 mmol), oleylamine (6 mmol), and benzyl ether (20 mL). The 
mixture was heated to reflux for y min at 300 °C, with a heating rate of 8 °C/min, under an argon 
atmosphere and cooled down to room temperature. Under ambient conditions, ethanol was added to the 
mixture resulting in black precipitate via centrifugation (4500 rpm, 10 min). The black powder was 
dissolved in hexane.  
3.2.2 Synthesis of Zn0.4Co0.6Fe2O4@xZn0.4Mn0.6Fe2O4 nanoparticles  
xZn(acac)2 (0.4 mmol) , xMn(acac)2 (0.6 mmol), and xFe(acac)3 (2 mmol) were placed in a 50 mL three-
neck round-bottom in the presence of oleic acid (6 mmol), oleylamine (6 mmol), and benzyl ether (20 mL). 
After the addition of the Zn0.4Co0.6Fe2O4 nanoparticles suspended in hexane, the mixture was first heated 
to 100 °C for 30 min to remove the hexane, and then heated to reflux 300 °C for 60 min under an argon 
atmosphere with a heating rate of 8 °C/min. After cooling, the ethanol was added to the mixture resulting 
in black precipitate. The obtained precipitate was dispersed in toluene after centrifugation. 
3.3 PART III 
3.3.1 Synthesis of truncated octahedron Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 nanoparticles 
The CS-MNPs were synthesized by the same method described in section 3.2 with different experimental 
parameters. 
3.3.2 Conjugation of DOX to Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 nano-carriers via thermo-responsive switch 
As-synthesized magnetic nanoparticles (50 mg) were mixed with a solution of alendronic acid (100 mg 
alendronic acid in 25 mL water) and heated for 90 min at 90 °C. The alendronic acid in excess was removed 
by washing and centrifugation. 2-furfuryl isothiocyanate (100 µL) was added to solution and stirred for 20 
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h at 45 °C. The excess of 2-furfuryl isothiocyanate was eliminated by washing with distilled water and 
centrifugation for several times. Afterwards, N-(2-Carboxyethyl)maleimide (0.44 mmol) was added and 
stirred for 20 h at 45 °C. The excess of N-(2-Carboxyethyl)maleimide was removed by washing with PBS. 
Functionalized nanoparticles (1 mg/mL) were mixed with EDC (20 mg), NHS (20 mg), and DOX (1 mg) and 
stirred for 24 h at 37 °C. The DOX-loaded nanoparticles were purified by washing and centrifugation 
several times with distilled water and stored in a refrigerator in the dark before further experiments. 
3.4 PART IV 
3.4.1 Synthesis of spherical Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 nanoparticles 
The CS-MNPs were synthesized by the same method described in section 3.2 with different experimental 
parameters. 
3.4.2 LBL coating of core/shell magnetic nanoparticles 
A standard LBL technique was used to coat the nanoparticles. CS-MNPs (2 mg/mL) was added drop-wise 
during 20 min to aqueous solution of PAH (4 mg/mL) under sonication. The mixture was kept under stirring 
in the dark and at room temperature during 12 h. The excess of PAH was removed by washing and 
centrifugation several times with water. Then PAH coated nanoparticles were mixed with PAA (4 mg/mL) 
during 20 min. The mixture was stirred for 12 h in the dark at room temperature and then purified. The 
given procedure was repeated until the required number of layers was reached. 
3.4.3 Doxorubicin loading onto the last layer (PAA) of the coating 
LBL-coated nanoparticles (1 mg/mL, pH 7) were mixed with N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC) (10 mg) and N-Hydroxysuccinimide (NHS) (10 mg). The solution 
was agitated for 5 h at room temperature. The excess of EDC and NHS was removed by washing and 
centrifugation several times with PBS. DOX (2 mg) was added to the mixture and stirred for 24 h at 37 °C. 
The DOX loaded CS-MNPs were purified by washing and centrifugation several times and kept refrigerated 
at 4 °C in the dark before further experiments. 
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3.5 CHARACTERIZATION OF CORE/SHELL MAGNETIC NANOPARTICLES AND ITS FUNCTIONALIZATION 
3.5.1 X-ray diffraction (XRD) 
A PANanalytical X’Pert Pro MPD X-ray diffractometer was used to determine the crystalline structure of 
nanoparticles. The diffractograms were recorded using CuKα radiation (λ=1.54 Å) at room temperature 
with a step size of 0.02o and a count rate of 2s/step. The mean crystallite size of the nanoparticles was 
calculated by Scherrer´s formula from the (311) Miller plane of the diffraction pattern. 
3.5.2 Transmission electron microscopy (TEM) 
TEM analyses were performed on a JEOL JEM-2010 instrument with spatial resolution of 1.4 Å (lattice) 
and 1.94 Å (point to point).   
3.5.3 X-ray photoelectron spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) analysis was realized by means of ULVAC PHI 5000 Versa Probe II 
spectrometer with monochromated Al Kα (1486.7 eV) X-ray radiation. All binding energies were 
referenced to the carbon 1s peak at 284.6 eV. The spectra were processed with the ULVAC-PHI MultiPak 
software and the residual background was removed using the Shirley method. 
3.5.4 Dynamic light scattering (DLS) 
The hydrodynamic diameters of the samples were determined by DLS using an ALV 5000 spectrometer 
equipped with a Neodymium YAG-laser (λ = 532 nm) at 90o scattering angel. 
3.5.5 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR measurements were performed on a Bruker Vertex 70 spectrometer under ambient atmosphere (20 
scans at a resolution of 4 cm−1) in attenuated total reflectance (ATR) mode. The IR data were processed 
by means of OPUS v.6.5 (Bruker) software package. 
3.5.6 Thermogravimetry (TG)  
TG analysis was performed on a Netzsch Iris TG 209C device. The sample was placed in an alumina crucible 
and heated from room temperature to 700 °C under nitrogen atmosphere with a rate of 20 oC/min. 
3.5.7 Zeta potential 
For Zeta potential measurements a Malvern Instruments Zetasizer 3000 HSA was used.  
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3.5.8 Vibrating sample magnetometery (VSM) 
Room temperature magnetic measurements were done by a vibrating sample magnetometer (MicroMag 
3900, Princeton Measurements Corp., U.S.A) which provides a maximum magnetic field of 1 T. 
3.5.9 In vitro hyperthermia 
Magnetic heating measurements were performed to assay the heating performance of the nano-carriers. 
The SAR is commonly employed to quantify the heat dissipation rate of a given ferrofluid. SAR 
measurements of the nanoparticles in water were carried out using two devices: Hüttinger Elektronik, 
model IG5, which provides an AMF at 1950 kHz and power values up to 7.2 kW; Hüttinger Elektronik, 
model TIG 20/300, that uses a frequency of 400 kHz and power values up to 20 kW. The ferrofluid sample 
with a concentration (1 mg/mL) was inserted in a water-cooled magnetic induction coil. The temperature 
changes during time were recorded using a computer-attached fiber optic temperature sensor (OPT 
OCON AG).  
3.5.10 In vitro drug release assay 
For release measurements, DOX loaded particles (10 mg) were dispersed in phoshphate buffer saline (10 
mL) of pH 5 and/or 7.4. The release experiments were performed at 43 °C under HF-AMF (1950 kHz). At 
predetermined time intervals, the media taken out for measurement was replaced with an equal volume 
of fresh buffer solution. The drug release from magnetic nano-carriers was determined by fluorescence 
spectrometry (FP-6500 Spectrofluorometer) measuring the emission of the released DOX in the 
supernatant at excitation wavelength of 490 nm. The supernatant was obtained by magnetic decantation 
of magnetic nano-carriers. 
3.5.11 Cytotoxicity assay 
For the determination of cell viability the colorimetric MTT metabolic activity assay was used. HeLa cells 
(3 × 104 cells/well) and Hep G2 cells (1 × 104 cells/well) were cultured in a 96-well plate and incubated for 
12 h in the incubator. The cells were treated with culture medium containing functionalized CS-MNPs at 
different concentrations (12.5–200 μg) and incubated for another 24 h. Afterwards, the cells were washed 
with PBS for several times to remove free functionalized CS-MNPs. Cytotoxicity of CS-MNPs was further 
determined by MTT assay. MTT solution (1:10 dilution; 1 mL of MMT stock solution with 9 mL medium) 
was added to each well and incubated for 2 h. After the supernatant was removed, dimethyl sulfoxide (80 
μl) was added to dissolve the formazan crystals. The absorbance spectrum of each well was measured at 
550 nm excitation wavelength by spectrophotometry. The relative cell viability (%) was expressed with 
respect to the negative control wells. 
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4 RESULTS AND DISCUSSIONS 
The results obtained in this work are presented in this chapter. Four parts are included: the effect of Zn 
substitution on the structural and magnetic properties of ZnxCo1-xFe2O4@MnFe2O4 in part I; the effect of 
experimental parameters on the magnetic properties of Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 in part II; The 
third and fourth part of this thesis explain specific examples in which the concepts of part I & II were used 
to design magnetic drug targeting system for synergistic anticancer therapy. Part III concern about on-
command controlled drug release by Diels-Alder reaction using bi-magnetic core/shell nano-carriers; and 
On-Off switch controlled doxorubicin release from thermo- and pH-responsive coated bi-magnetic nano-
carriers in part IV. 
4.1 PART I 
The section deals with preparation of core/shell ZnxCo1-xFe2O4@MnFe2O4 nanoparticles via seed mediated 
growth, and attempts to investigate the influence of Zn+2 substitution on the structure and magnetic 
properties of CS-MNPs, which can enhance SAR for hyperthermia application. 
Thermal decomposition of Fe(acac)3 and controlled consecutive reduction of Zn(acac)2 and Co(acac)2 or 
Mn(acac)2 with oleic acid and oleylamine at high temperature yield monodisperse core/shell ZnxCo1-
xFe2O4@MnFe2O4 nanoparticles, which can be easily precipitated from the solution by adding ethanol. The 
success of forming monodisperse nanoparticles is because of directly slow heating to reflux at 298 °C with 
heating rate 8 °C/min in benzyl ether.  
4.1.1 Effect of Zn substitution on the structural properties of magnetic nanoparticles 
The nominal molar compositions of the prepared samples were CoFe2O4@MnFe2O4, 
Zn0.2Co0.8Fe2O4@MnFe2O4, Zn0.4Co0.6Fe2O4@MnFe2O4, Zn0.6Co0.4Fe2O4@MnFe2O4, and 
Zn0.8Co0.2Fe2O4@MnFe2O4 for S1, S2, S3, S4 and S5 samples, respectively. 
The XRD patterns clearly show that all samples have a cubic spinel structure and are shown in figure 4.1. 
There is a shift in 2θ towards lower angles with increasing Zn substitution, revealing an increase in the 
lattice parameters of the samples. The crystallite sizes for these samples are 8.2 ± 0.5 nm (S1), 9.3± 0.4 
nm (S2), 10.1 ± 0.2 nm (S3), 11 ± 0.3 nm (S4), and 12.2± 0.4 nm (S5).  
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Figure 4.1. XRD patterns of different nanopowders 
 
The XRD patterns of the samples are refined using the Rietveld profile fitting technique. The refinement 
is carried out by using the PANalytical X'Pert HighScore program and assuming a cubic structure with the 
Fd3m space group (figure 4.2a).  Figure 4.2b shows that the lattice parameter increases from 8.36 Å to 
8.394 Å with increasing Zn concentration. This could be related to the change in the ionic size of zinc. 
When Zn2p is substituted, it prefers the A site [62] and an increase in the lattice parameter is expected as 
the larger Zn2p (0.74 Å) ions replace the Co2p ions (0.65Å) [63] and lead to an expansion of the structure 
and, consequently, to an increase of the lattice parameter.  
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Figure 4.2. a) A typical XRD pattern with Rietveld analysis of S2, b) Variation of the lattice parameter (Å) of the 
samples with Zn concentration. 
 
The properties of magnetic nanoparticles are expected to be dependent critically on the morphology of 
the samples. The morphology of the samples was determined by TEM. The mean size of the CS-MNPs 
have been evaluated by TEM images (Figure 4.3a–e) and confirmed by DF-TEM (Figure 4.3f). The mean 
average size of the core/shell systems was calculated as 9± 0.5 nm (S1), 10.7 ± 0.4 nm (S2), 11.5 ± 0.6 nm 
(S3), 12 ± 0.3 nm (S4), and 13.2 ± 0.7 nm (S4). The crystallite size from XRD results comparable with the 
average particles size determined from TEM images, indicate that the nanoparticles have high crystallinity. 
The morphology of S3 is different from other samples, which is more related to cubic shape, while the 
shape of other samples is spherical to truncated octahedron. Thus it will affect the magnetic properties 
of the samples. 
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Figure 4.3. TEM images of: a) S1; b) S2; c) S3; d) S4; e) S4 and e) DF- TEM image of S2. 
 
XPS measurements were performed to investigate the valence change of the cations and chemical 
composition of the samples (figure 4.4a). The XPS analysis indicated that all samples are composed of Fe, 
Co, Mn, and O. Moreover, sample S2-S5 contain of Zn. Figure 4.4b-f displays XPS deconvolution spectra 
of S3. 
The XPS spectrum of Co2p exhibits two peaks located at binding energies (BE) of 781 and 796.4 eV, which 
can be attributed to Co2p3/2 and Co2p1/2, respectively (Figure 4.4b); they are accompanied with 
corresponding shake ups peaks at 786.5 and 802.7 eV, respectively, indicates Co+2 occupy the octahedral 
sites in the CS-MNPs spinel lattice.[64]  In the Mn2p spectrum (Figure 4.4c), the dominant peak Mn2p3/2 is 
at 642.2 eV and the other peak Mn2p1/2 is at 653.8 eV, providing a clear evidence for Mn2+ chemical state 
on the sample surface.[65] The Mn2p3/2 spectra have peaks located at 640.4, 642.4, and 646.6 eV,  which is 
29 
 
in good agreement with the value reported for the Mn2+, Mn4+, and its satellite, respectively.[66] The Fe2p 
spectra show the two main peak with binding energies of the Fe2p3/2 and Fe2p1/2 core levels located at 
711.2 and 724.3 eV, respectively (Figure 4.4d), with corresponding satellite peaks for Fe2p3/2 and Fe2p1/2 
visible at binding energies of around 719.2 and 731.0 eV, which is consistent with that reported for Fe3+ 
cations.[67] In principle, the satellite peak with the main peaks appears due to two final states caused by 
photoemission of the Fe site of the oxide. The peak with the binding energy of 711.2 eV is attributed to 
the Fe3+ cation located at the octahedral sites in the spinel structure. The binding energies of the Zn2p3/2 
and Zn2p1/2 core level peaks are 1021.4 and 1044 eV, respectively, confirming the presence of Zn2+ cation 
(Figure 4.4e). The peak at 1021.3 eV is ascribed to Zn2+ cations occupying tetrahedral site in CS-MNPs.[68] 
The O1s peak is deconvoluted into two contributions at 530 and 531 eV, which are attributed to the crystal 
lattice oxygen and surface-adsorbed oxygen, respectively (Figure 4.4f). 
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Figure 4.4. a) XPS spectra of CS-MNPs samples. Fitted photoelectron peaks of: b) Co2p1/2 and Co2p3/2; c) 
Mn2p1/2and Mn2p3/2; d) Fe2p1/2 and Fe2p3/2; e) Zn2p1/2 and Zn2p3/2; f) O1s. 
 
4.1.2 Effect of Zn substitution on the magnetic properties of magnetic nanoparticles 
The effects of Zn substitution on the Ms, Mr, and Hc of the samples are listed in Table 4.1 and it shows the 
variation of Mr and Hc, which decreases with the increase in zinc substitution. 
 
Table 4.1. Comparison of magnetic properties of different samples 
Sample Ms (emu/g) Mr (emu/g) Coercivity (Oe) 
S1 44.9 0.72 222 
S2 54.3 0.3 15.4 
S3 61.5 0.25 6.3 
S4 51.5 0.21 4.3 
S5 47.1 0.17 2.2 
 
 
The magnetic measurements of the samples are shown in Figure 4.5. The magnetization curves display a 
superparamagnetic behavior of the systems that could be explained by the small-size effect of the 
nanoparticles. For low substituted (x= 0, 0.2, 0.4) zinc, Ms increased from 44.9 to 61.5 emu/g and 
decreased thereafter to a value 47.1 emu/g when x was increased further to 0.8.  
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Figure 4.5. Magnetic hysteresis loop of the different nanopowders 
 
The variation of Ms is due to the cation distribution between the tetrahedral (A) and octahedral sites (B) 
of cations. The increase in Ms can be explained by the fact that, when a small amount of Zn2p is substitutes 
Co2p, it has a strong preference to occupy the tetrahedral sites.[69]  Consequently, it displaces Fe3p ions 
from the tetrahedral sites to the octahedral sites. This induces the partial removal of antiferromagnetic 
coupling interactions between Fe3+ ions in the tetrahedral sites and the octahedral sites,[70] which can 
increase the magnetization of the samples based on the Neel's collinear two-sub-lattice model.[71]  
Further increase in the Zn substitution with x from 0.4 to 0.8 resultes in a decrease in Ms from 76.78 to 
64.89 emu/ g. This decrease of Ms can be explained on the basis of the three sub-lattice model suggested 
by Yafet-Kittle model.[72] The triangular spin arrangement on B-sites is favorable, which decrease the A-B 
interaction and increase of B-B interaction. As a result of this phenomena, the antiferromagnetic coupling 
interactions between Fe3+ ions in each octahedral site are dominant which decreases the Ms. 
The shape anisotropy plays a key role in determining the magnetic properties of nanoparticles.  For the 
particle with large surface to volume ratio, the surface contributions to the magnetic properties become 
important, thus the surface anisotropy (Ks) associated with the shape becomes significant where surface 
anisotropy is created from the different spin direction between core and surface.[73] Therefore, cube shape 
(S4), having a smaller surface anisotropy, hence reduced spin disordering is advantageous to attain a 
larger Ms compared to a spheres.  
-10000 -5000 0 5000 10000
-80
-60
-40
-20
0
20
40
60
80
 
 
 S1
 S2
 S3
 S4
 S5
M
a
g
n
e
ti
z
a
ti
o
n
  
(e
m
u
 /
g
)
Field (Oe)
32 
 
Figure 4.6a shows the temperature versus time, measured at 1980 kHz frequency and in a power of 1592 
W, for all samples. The maximum temperature change exceeding 320 K was observed for S3, whereas the 
samples with higher or lower Zn content demonstrated lower heating. 
The investigation of the hyperthermic efficiency of the CS-MNPs was performed by evaluating the SAR. 
The SAR values were estimated from the initial slope of the temperature versus time curves (dT/dt). The 
efficiency of heating for a magnetic fluid is described by the SAR.[74]  
 
                                                              SAR =
𝑐
𝑚
×
𝑑𝑇
𝑑𝑡
                                                             (4.1) 
 
where C is the specific heat capacity of the medium, and m is the mass of the sample. 
Figure 4.6b present the variation of SAR with power of different Zn-substituted CS-MNPs at high frequency 
(1950 kHz). The graph shows that the S1 provides a low SAR, while a sizeable value is measured once the 
samples are doped with a small amount of Zn ions (S2). Interestingly, the SAR further increases with 
increase in the amount of doping, reaches a maximum for S3, but it drops down for S5. The SAR value of 
S3 is twice SAR value of the core (Zn0.4Co0.6Fe2O4), indicating that the magnetic nanoparticles are 
interfacial exchange coupled between hard and soft magnetic phases. 
  
Figure 4.6. a) Heating process of different samples, b) The SAR functions for the frequency (1955 kHz) of samples. 
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The heating power depends not only on the parameters of the external applied field H0 and the frequency 
f, but also on the magnetization of the material, and on the characteristic time of the magnetization 
reversal. The power loss density (W/m3) due to Neel relaxation and Brownian relaxation is expressed as 
[33]. 
                                                                 𝑆𝐴𝑅 𝛼 𝑓𝐻0𝑀𝑠
2𝑉 (
2𝜋𝑓𝜏
1+(2𝜋𝑓𝜏)2
)                                     (4.2) 
 
 
For small nanoparticles in the single-domain or superparamagnetic range, heating arises from the Néel 
and Brownian relaxation. Néel relaxation dominates when the nanoparticles are less than 20 nm.[75] This 
further implies that the Brownian relaxation in the samples does not contribute to the heat dissipation 
mechanism, therefore assuming the control of the hyperthermic effect independently of any external 
parameter. Tuning the magnetic properties of nanoparticles through the control of their nanostructure 
will contribute to the development to optimized agents for hyperthermia. The fast inductive heat 
generation of nanoparticles increases the efficacy of cell death hyperthermia and reduces the toxicity 
during therapy. 
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4.2 PART II 
In this part we focused on chemical synthesis of truncated octahedron CS-MNPs in order to improve their 
SAR. We investigated microstructural and magnetic properties of CS-MNPs system with hard core 
(Zn0.4Co0.6Fe2O4) and tunable thickness of soft shell (Zn0.4Mn0.6Fe2O4). The thickness of the shell is tuned 
by varying the concentration of the precursor, while the shape and the size of the core are controlled by 
the time of reaction. We demonstrated an increase of SAR of CS-MNPs compared with the magnetic core, 
indicating that the core and the shell are effectively exchange coupled. As a result, the magnetic 
properties, such as SAR and Ms of these CS-MNPs could be controlled by tuning the core/shell physical 
parameters and chemical compositions. 
4.2.1 Effect of experimental parameters on the structural properties of magnetic nanoparticles 
Four CS-MNPs samples were synthesized using seed mediated growth. Two samples have the same core 
diameter (7 nm), but different shell thicknesses of 2±0.3 nm (Sample S1) and 1±0.1 nm (Sample S2) 
respectively. Other two samples have the core diameter of 5 nm and shell thicknesses of 2±0.2 nm (Sample 
S3) and 1±0.1 nm (Sample S4), respectively. The mean size of the CS-MNPs and the thickness of the shell 
have been evaluated by TEM images (Figure 4.7a–d) and confirmed by DF-TEM (Figure 4.7e). The mean 
average size of core/shell systems was calculated as 9.3± 0.5 nm (S1), 8.1 ± 0.5 nm (S2), 7.0 ± 0.6 nm (S3), 
and 6.2 ± 0.4 nm (S4). 
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Figure 4.7. TEM images of: a) S1; b) S2; c) S3; d) S4 and e) DF- TEM image of S1. 
 
Figure 4.8a shows the XRD patterns of all samples. The XRD pattern and the Rietveld profile refinement 
of S1, using the PANalytical X'Pert HighScore program are shown in Figure 4.8b. Based on these result the 
Bragg reflections of all samples match the reported values for the face-centered cubic structure with the 
space group Fd3m (Powder Diffraction Files, card no 22-1086 and no.89-1009). No evidence of impurity 
phases was detected.  The mean crystallite size for all samples are 8.2 ± 0.5 nm (S1), 7.3± 0.4 nm (S2), 6.2 
± 0.3 nm (S3), and 5.4± 0.3 nm (S4). We note an increase of the mean crystallite size with the increasing 
of the concentration of the precursor and the reaction time. 
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Figure 4.8. X-ray diffraction patterns of different nanopowders. b) a typical XRD pattern 
 
Figure 4.9 exhibits that the lattice parameter of the samples and it increased from 8.371 Å to 8.394 Å. This 
could be related to the variation of particle size versus the concentration of the precursor and the reaction 
time.  
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Figure 4.9. The lattice parameter (Å) of the samples 
 
To verify the composition of the Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 nanopowders, XPS analysis was applied 
to investigate the binding energy of surface atoms present in the samples. The XPS analysis indicated that 
all samples are composed of Fe, Co, Mn, Zn, and O (Figure 4.10a). 
The XPS spectrum of Co2p recorded from sample S1 are characterized by binding energies of the Co2p3/2 
and Co2p1/2 core levels of 781 and 796.4 eV, respectively, with corresponding shake ups peaks at 786.5 
and 802.7 eV, respectively (Figure 4.10b). This confirms that the Co2+ cations occupy the octahedral sites 
in the CS-MNPs spinel lattice. From the Mn2p spectrum, it was found that the peak at 640.4 eV is from 
Mn2p3/2, with a satellite peak at 646.6, while the peak at 652.3 eV is caused by Mn2p1/2 with a satellite 
peak at 657.8 eV (Figure 4.10c). This result provides a clear evidence for Mn2+ chemical state on the sample 
surface. The Fe2p spectra show the two main peaks with binding energies of 711.2 and 724.3 eV which 
were respectively assigned to Fe2p3/2 and Fe2p1/2, and accompanied by two satellite peaks at binding 
energies of 719.2 and 731.0 eV (Figure 4.10d), which is indicative of the presence of Fe3+ cations The 
binding energies of the Zn2p3/2 and Zn2p1/2 core level peaks are 1021.4 and 1044 eV (Figure 4.10e), 
respectively confirming the presence of Zn2+ cations in tetrahedral site. The O1s peak is fitted to two peaks 
at 530 and 531 eV (Figure 4.10f), which are ascribed to the featured of the crystal lattice oxygen and 
surface-adsorbed oxygen, respectively. 
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Figure 4.10. a) XPS spectra of different samples. Fitted photoelectron peaks of: b) Co2p1/2 and Co2p3/2; c) 
Mn2p1/2and Mn2p3/2; d) Fe2p1/2 and Fe2p3/2; e) Zn2p1/2 and Zn2p3/2; f) O1s. 
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All samples were studied with EDX analysis to examine the elemental composition of the particles. Figure 
4.11a shows the EDX analysis of S1. The peaks assigned to Fe, Co, Mn, Zn, C and O elements can be clearly 
observed. Figure 4.11b shows the variation of cobalt and manganese in different samples, which confirms 
that the amount of cobalt and manganese in the samples is increasing with increasing the concentration 
of precursor and the reaction time. 
 
  
Figure 4.11. a) The typical EDX analysis of S1. b) The variation of Co and Mn in the samples. 
 
4.2.2 Effect of experimental parameters on the magnetic properties of magnetic nanoparticles 
Figure 4.12a shows the temperature versus time, measured at 1980 kHz frequency and in a power of 2574 
W, for all samples are investigated. It can be seen that the S4 show a higher heating process after 80 sec, 
which go towards lower temperature with the core; 316 K for S1, 314.4 K for S2, 312.5 for S3, 310.4 K for 
S4, 306.3 K for core (7 nm), and 304.7 K for core (5nm).   
Several methods of Tc determination are hardly applicable to ferrofluids: magnetization measurements 
are not possible at temperatures above the boiling point of the dispersion medium (e.g. water); optical 
methods suffer from the extremely high optical absorption and are restricted only for strong diluted 
magnetic colloids.  
Using a calorimetric measurement technique we found a clear correlation between the temperature 
dependence of the magnetization of the ferrites and the energy absorption in an AMF. As we are limited 
to temperatures below the boiling point of the carrier liquid, we applied an extrapolation method to 
calculate the energy absorption up to the Tc of the nanoparticles. In this way we obtained an estimate of 
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the Tc of the magnetic nanoparticles in dispersion. As novelty, this determination of the Curie point is 
completely based on measurements made in the colloidal dispersion. 
Under the ideal condition of non-interacting, monodisperse particles, the fitting functions for (dT/dt) 
versus T for both the heating and the cooling process is often referred as to the Tc.[76]  
As a result, by using a linear extrapolation for the cooling and heating branches, we expect to have Tc as 
the intersection point of temperature change over time with temperature (Figure 4.12c), and yields 394 
K, 378 K, 368 K, and 360 K for samples S1, S2, S3, and S4, respectively. The decrease of Tc with the decrease 
in particle size in the present case is attributed to the fluctuations of the electron spins become more 
prominent in the smaller size of particles.[77] The dependence of the Tc on size confirmed by most of 
studies.[78]  
Since the calorimetric measurements have been made at low temperatures we avoided undesired effects 
like particle growth, inhomogeneous radiative heat transfer and phase conversion to another 
ferromagnetic phase. Also, we have the advantages of short time measurements, accurate temperature 
uniformity, high power measurements and direct determination of the losses. The method allows for an 
accurate measurement of the temperature absorption of magnetic fluids in high frequency magnetic 
fields, a feature which is of outstanding importance for biomedical applications. 
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Figure 4.12. a) Heating process of different samples. b) Temperature variation rate in unit time (dT/dt) with 
exposure time of S1. c) Temperature change rate in unit time (dT/dt) versus time of S1. 
 
Figure 4.13 shows the room temperature field dependent magnetization curves for different size of 
Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 (6–10 nm). The magnetization curve of CS-MNPs in powder form was 
measured at 300 K in external magnetic fields from -1 T to 1 T. All samples show superparamagnetic 
properties with low Hc values as well as remanence magnetization. We find Ms shows an increasing trend 
with the increasing of the size of CS-MNPs as seen in table 4.2. The 1 T magnetization at 300 K decreases 
from 59.6 emu/g for the S1 particles to 42.8 emu/g for the S4 particles. The magnetization curves of all 
samples display a superparamagnetic behavior that could be assigned to the small-size effect of the 
nanoparticles, which is important in biomedical applications whereas the nanoparticles aggregation or 
cluster formation should be avoided. 
 
Figure 4.13. Magnetic hysteresis loop of the different sizes Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 nanopowders 
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Table 4.2. Comparison of magnetic properties of different size Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 
Sample Ms (emu/g) Mr (emu/g) Hc (Oe) Tc (K) 
S1 59.6 0.2 4.2 394 
S2 53.3 0.1 2.4 378 
S3 47.3 0.17 3.6 368 
S4 42.8 0.21 3.4 360 
 
CS-MNPs possess a disordered spin layer at their surfaces, and when the size of the nanoparticle is small, 
the ratio of disordered layer to the radius of the CS-MNPs is significant. Surface spin disorder thus leads 
to reduced Ms for smaller nanoparticles as defined here:[79] 
 
                                                             𝑴𝒔 = 𝑴𝒔𝒃  [
𝒓−𝒅
𝒓
]
𝟑
                                       (4.3) 
 
Where r is the radius, d is the thickness of the MNPs surface exhibiting disordered spins, and Msb is the 
bulk Ms. We emphasize that the reduced Ms values arise from the spin-disorder effect. 
The efficiency of heating for a magnetic fluid is described by the SAR (equation 4.1). The SAR values that 
arise from the relaxation processes are roughly proportional to the Ms and magnetocrystalline anisotropy 
constant (K), and are inversely proportional to the size distribution of the nanoparticles.[80] 
Figure 4.14 present the variation of SAR with power of different size of Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 
at two frequencies (1950, 450 kHz). The graphic shows a linear variation of SAR with power. The SAR values 
of all the samples show an increase with an increase in size of CS-MNPs. In addition to this, however the 
samples (S3 and the core) have the same size, the observed SAR values for S3 are found to be higher as 
compared to that of the single-component magnetic nanoparticles. This clearly indicates that the obtained 
Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 nanoparticles are magnetically exchange-coupled.  
In the case of 9 nm S1 nanoparticles the maximum 521 W/g SAR value was obtained, whereas for the 6 
nm S4 particles the values didn’t exceed 340 W/g at an AC field of 5677 W (Figure 4.14a). We observe 
here that the magnitude of the SAR value increases as the particle size increased and the frequency 
decreased (Figure 4.14b).  
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Figure 4.14. The SAR functions for the frequencies a) 1955, and b) 450 kHz of samples 
This increase in SAR values indicates that the magnetic coupling may play an important role in defining 
the heating mechanisms. The magnetic exchange coupling between nanocrystals lead to decrease of the 
anisotropy energy, which allows increase of the total magnetic moment for magnetic nanoparticles.[81]  
In the case of large nanoparticles, heating occurs due to the hysteresis losses and the Brownian relaxation. 
For small nanoparticles in the single-domain or superparamagnetic range, heating arises from the Neel 
and Brownian relaxation. Neel relaxation dominates when the nanoparticles are less than 20 nm, and 
Brownian relaxation dominates when the nanoparticles are larger than 20 nm.[75] In the case of our 
systems the increase of heating efficiency with CS-MNPs size is attributed to the Neel relaxation of 
nanoparticle. Another related parameter which strongly influences the SAR value is the shell thickness. 
The impact of the thickness of the CS-MNPs on magnetic properties has been studied by varying the 
precursor concentration. As expected from the increased shell thickness made in sample S1, it was 
observed the highest SAR. So increasing the shell thickness will enhance the exchange reaction in CS-
MNPs.  Also the shape of magnetic nanoparticle is a key factor which influences magnetic properties. Noh 
et al. showed that the SARs of CS-MNPs were influenced by the shape of magnetic nanoparticle, and also 
observed that cubic Zn0.4Fe2.6O4 had a higher Ms as compared to spherical MNPs of the same volume.[61] 
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4.3 PART III 
We performed the functionalization of the CS-MNPs via DA reaction for bonding of DOX via a 
corresponding linker and later the rDA reaction for dis-bonding. The method uses the property of the 
reversible breaking of C=C bond as thermo-responsive switch. The drug release rate is controlled on-
demand by switching the external magnetic field. With a fast heating rate of magnetic colloid and a carbon 
bond/disbond thermally activated mechanism in the nanoparticles, an accelerated drug release rate could 
be achieved (scheme 4.1).  
 
 
 
Scheme 4.1. Retro-Diels-Alder reaction mechanism 
4.3.1 Structural characterizations of truncated octahedron magnetic nanoparticles 
The XRD pattern of the nanopowder is shown in Figure 4.15 The Bragg reflections indexed to planes (220), 
(311), (400), (422), (551), (440) and (335) match with the reported values of the face-centered cubic (fcc) 
unit cell of the spinel structure with the space group Fd-3m (card no. 98-007-9524, PDF-4 Database). No 
residual phases were observed. The mean crystallite size is 7.8±0.4 nm. 
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Figure 4.15. XRD pattern of CS-MNPs 
 
The mean hydrodynamic diameter of the CS-MNPs dispersed in hexane, investigated by DLS, was 
calculated as 10.9±0.5 nm. The TEM measurements of CS-MNPs nanoparticles are displayed in Figure 
4.16a. The images suggest a polyhedron-type shape of essentially monodispersed nanoparticles with a 
mean diameter of 9.7±0.4 nm. The DF-TEM confirm the CS-MNPs morphology of hard/soft magnetic 
phases (Figure 4.16b). The shell thickness was evaluated as 2±0.3 nm. 
 
   
Figure 4.16. a) TEM and b) DF-TEM micrographs of CS-MNPs. 
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XPS was performed to analyze the valence state of the cations and chemical composition of the CS-MNPs. 
Figure 4.17a shows the XPS photoemission peaks of O1s, Mn2p, Co2p, Zn2p, and Fe2p core levels. The 
Co2p spectrum has been deconvoluted into four contributions (Figure 4.17b). The first two peaks with 
binding energies (BE) of 782.11 and 787.50 eV are attributed to Co2p3/2 and its satellite, whereas the peaks 
centered at 797.32 and 802.65 eV correspond to Co2p1/2 and its satellite, respectively. The Co2p1/2 and 
Co2p3/2 peaks proved the Co2+ species in an octahedral spinelic structure.[82] Their corresponding satellites 
with BE splitting of 6.2 eV confirm the Co bivalent cations in the octahedral sites.[83,84] Two broad and 
asymmetric peaks at 642.0 and 653.3 eV (Figure 4.17c), correspond to Mn2p3/2 and Mn2p1/2, 
respectively.[85] The Mn2p3/2 photoemission peak can be deconvoluted into three contributions centered 
at 640.4, 642.4, and 646.6 eV, attributed to Mn2+, Mn4+ (that suggests oxidation of Mn2+ cations), and its 
satellite, respectively.[66,86] The asymmetric Mn2p3/2 peak indicates the presence of mixed-valence 
manganese cations. The co-presence of manganese in different oxidation states is consistent with 
reported data on the MnFe2O4 structural phase.[87] The XPS spectrum fitting of Fe2p displays the peaks of 
Fe2+ and Fe3+ cations and its satellites (Figure 4.17d). The Fe2p peaks are composed of two main 
asymmetric peaks, Fe2p3/2 and Fe2p1/2 with BE centered at about 711.0 and 725.0 eV respectively, and 
match to α-Fe2O3 phase formation. The BE centered at 711 eV is attributed to Fe3+ cations in the spinel 
structure.[88] In addition, the two common satellite peaks at 719.72 and 732.40 eV confirmed the Fe 
oxidation states of CS-MNPs.[89] Fe3O4 does not show any satellite peak due to overlapping of two satellite 
peaks corresponding to Fe3+ (at 8.0 eV) and Fe2+ (at 6.0 eV).[90] Figure 4.17e shows the Zn2p high resolution 
XPS spectrum. The Zn2p3/2 and Zn2p1/2 core level peaks at 1021.4 and 1044 eV, respectively, are in 
agreement with the oxidation state of Zn2+ in the sample.[91,92] The peak at 1021.4 eV confirms the Zn2+ 
occupying octahedral sites.[93] The O1s peak is deconvoluted into two contributions at 530 and 531 eV, 
that are attributed to the crystal lattice oxygen and surface-adsorbed oxygen, respectively (Figure 
4.17f).[94] 
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Figure 4.17. a) XPS spectra of CS-MNPs. Fitted photoelectron peaks of: b) Co2p1/2 and Co2p3/2; c) Mn2p1/2and 
Mn2p3/2; d) Fe2p1/2 and Fe2p3/2; e) Zn2p1/2 and Zn2p3/2; f) O1s. 
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The effect of time on the colloidal stability of CS-MNPs capped with TMAOH was investigated by DLS. 
However, the time-dependent hydrodynamic diameter of the CS-MNPs does not show significant 
variation (Figure 4.18).  
 
Figure 4.18. Stability of CS-MNPs in water up to 8 weeks. 
 
4.3.2 Magnetic properties of truncated octahedron magnetic nanoparticles 
The magnetic measurements of CS-MNPs and functionalized CS-MNPs are shown in Figure 4.19. The 
magnetization curves display a superparamagnetic behavior of the systems that could be assigned to the 
small-size effect of the nanoparticles. This property is important in biomedical applications whereas the 
nanoparticles aggregation or cluster formation should be avoided.[95] The Ms of core-shell nanoparticles 
was calculated as 50 emu/g. The lower value of Ms (29 emu/g) of functionalized CS-MNPs could be 
explained by non-magnetic contribution of the surface layer that is accounted in the weight of the sample. 
A relatively high Ms of functionalized nanoparticles could be an important factor for magnetically targeted 
delivery system. 
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Figure 4.19. The magnetization curves of CS-MNPs and functionalized CS-MNPs. 
 
By using a linear extrapolation for the heating (upon AMF) and cooling branches, we can evaluate the Tc 
as the intersection point of temperature change over time (dT/dt) with temperature (Figure 4.20). The Tc 
of CS-MNPs in aqueous medium was estimated at 363 K. 
 
Figure 4.20. a) Temperature curves over time of CS-MNPs. b) Temperature change rate in unit time (dT/dt) versus 
temperature of CS-MNPs. 
 
In order to evaluate the heating performance on CS-MNPs, we have calculated the SAR according to the 
equation 4.1. Figure 4.21 displays the dependence of SAR with different power values at two frequencies 
for core and CS-MNPs. The SAR values of CS-MNPs were compared with those of single-component 
magnetic nanoparticles. The SAR of magnetic cores ranges from 20 to 130 W/g at 450 KHz and from 34 to 
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163 W/g at 1950 KHz. In contrast, for CS-MNPs SAR was estimated in the limits of 70 to 210 W/g at 450 
KHz and from 218 to 452 W/g at 1950 KHz. The SAR of core-shell nanoparticles is significantly higher than 
those of single component particles. This clearly indicates CS-MNPs are magnetically exchange-coupled 
and proved an important enhancement of magnetic heat induction.  
 
Figure 4.21. The dependence of SAR on electromagnetic power for the magnetic fluid samples at selected 
frequency values. 
 
4.3.3 Cytotoxicity assay of functionalized magnetic nanoparticles 
HepG2 is a perpetual cell line consisting of human liver carcinoma cells, derived from the liver tissue of a 
15-year-old Caucasian male who had a well-differentiated hepatocellular carcinoma. HepG2 can be grown 
in a large scale, and secret a variety of plasma proteins, such as transferring, fibrinogen, plasminogen and 
albumin. They can be stimulated with human growth hormone. HepG2 are adherent, epithelial-like cells 
growing as monolayers and in small aggregates.[96] HeLa cell is derived from a cervical carcinoma from a 
31 year old female and have served as a standard for understanding many fundamental biological 
processes. They have many basic characteristics as the normal cells, such as producing proteins, 
expressing and regulating genes, and are susceptible to infections.  
To determine the cytotoxicity of the functionalized CS-MNPs, The HeLa and Hep G2 cells were treated 
with culture medium containing functionalized CS-MNPs at different concentrations (12.5–200 μg) and 
incubated for another 24 h. The cell viability of Hep G2 is decreased to 87 % after 24 h of treatment within 
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maintains more than 90 % for the CS-MNPs (Figure 4.22b), indicating that the functionalized CS-MNPs are 
non-toxic. Therefore, it can potentially be applied as drug carriers for biological applications. 
  
Figure 4.22. Cell viabilities of functionalized CS-MNPs with a) Hep G2, and b) HeLa cells measured by MTT assay. 
 
4.3.4 Conjugation of doxorubicin to functionalized magnetic nanoparticles 
In the process of drug loading and releasing, the drug molecules (DOX) can be easily attached onto the 
surface of CS-MNPs through an amide bond. We prepared functional CS-MNPs according to figure 4.23. 
The CS-MNPs were first synthesized through a seed-mediated growth method. The particle surfaces (1) 
were modified with TMAOH in order to disperse the CS-MNPs in an aqueous media. To stabilize and 
functionalize the hydrophilic CS-MNPs, alendronic acid which has a primary amine (2) is used to form the 
thiourea compound (3) upon addition of 2-furfuryl isothiocyanate. The DA cycloadduct (4) was 
synthesized using the Furan-modified magnetic nanoparticle as dienes and N-(2-Carboxyethyl)maleimide 
as dienophiles.   
Prior to enable a rDA mediated release, DOX (5) was conjugated to the as-synthesized particles by amide 
conjugation in the presence of the crosslinkers EDC and NHS. Moreover, the drug-loaded nano-carriers 
could be targeted to the specific site under the application of an external magnetic field to improve drug 
release capability. The loading efficiency of nanoparticles is about 92%. 
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Figure 4.23. Illustration of the functionalization mechanism of CS-MNPs 
The FTIR analyses were performed in order to attest the functionalization on CS-MNPs (Figure 4.24). The 
spectrum of CS-MNPs confirms the presence of metal-oxygen intrinsic stretching vibrations in both 
octahedral (580 cm-1) and tetrahedral sites (620 cm-1) of the spinel lattice. Typical C-H vibration in the 
wavelength range of 2800-3000 cm-1 and a broad peak of C=O vibration of the carboxyl functional groups 
in the range of 1600 - 1750 cm-1 are attributed to the oleic acid, an intermediate in the synthesis. The 
spectrum of further TMAOH functionalized magnetic nanoparticles presents a vibrational band in the 
limits of 3000-3500 cm-1 that could be assigned to the adsorbed water molecules on the nanoparticles 
surface (sample 1). Two characteristic peaks of alendronic acid bonded to TMAOH, at 1635 cm-1 and 1125 
cm-1, are associated to P=O bending vibration and to C-N vibrational band, respectively (sample 2). The IR 
spectrum of CS-MNPs bearing furan shows the typical stretching vibration signals of C-H  (760 cm-1, 1240 
cm-1) and  C=C  (1510 cm-1) functional groups (sample 3). The disappearance of the antisymmetric S=C=N 
band between 2000-2100 cm-1 confirms the surface modification of the particles. The vibrational bands 
between 1700-1500 cm-1 correspond to C=O functional group that are specific to maleimide. The 
vibrational band of the acid amide group is located at 1650 cm−1 due to the -CO stretching vibration 
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(sample 4). The significant peaks observed at 1530 and 877 cm−1 corresponded to the C−N stretching 
vibrations and to the N−H bending vibration of −CO−NH− group, respectively, confirming the loading of 
DOX (sample 5).  
 
Figure 4.24. FTIR spectra of functionalized CS-MNPs. 
 
The TG curves of the functionalized nanoparticles are performed to prove the functionalization of the CS-
MNPs (Figure 4.25). The measurements showed that the mass loss increases with the increase in the 
reacting mass ratio. For all the patterns, a major weight loss was observed between 200 and 600 °C which 
is due to the thermal decomposition of the organic species on the CS-MNPs surface, as indicated by FTIR.  
The TG curve of sample 1 displays an initial weight loss (3.6 %). The weight loss in the temperature range 
30−120 °C is attributed to the removal of adsorbed water and to the hydroxyl groups that belong from 
TMAOH and/or alkanolamine.  The weight loss (13.12%) of Sample 2 in the temperature range 200-500 °C 
was associated to the alendronate desorption zone.  The TG curves of the sample 3 clearly shows a 
decrease in mass at an early stage (17.2 %), which is ascribed to the loss of the furan moieties. rDA reaction 
occurred for sample 4 in the heating process to generate some free maleimide and furan groups in the 
sample, which contributed to the increase of weight loss to 20.1 %. Crosslinking reaction occurred 
between some free maleimide groups enhancing its thermal stability and reducing the amount of weight 
loss at 400–500 °C. Finally, the significant weight loss (24.68 wt %) of sample 5 is attributed to the release 
of DOX. The mass loss decreased rapidly from approximately 250 °C to 400 °C, which can be associated to 
the rDA reaction and DOX decomposition. 
4000 3500 3000 2500 2000 1500 1000
0
20
40
60
80
100
120
140
160
 
 
T
ra
n
s
m
is
s
io
n
Wavenumber (cm
-1
)
 CS-MNPs
 CS-MNPs+TMAOH (1)
 CS-MNPs+TMAOH+Aledronic acid (2)
 CS-MNPs+TMAOH+Aledronic acid+Furan (3)
 CS-MNPs+TMAOH+Aledronic acid+Furan+Maleimide (4)
 CS-MNPs+TMAOH+Aledronic acid+Furan+Maleimide+Doxorubicin (5)
54 
 
 
Figure 4.25. TG patterns of functionalized CS-MNPs. 
 
4.3.5 Doxorubicin release profiles 
The thermo-responsive nano-carriers are desirable to preserve their payload at body temperature and to 
rapidly deliver the drug within locally heated tissue to overcome side effects as pathophysiological 
changes in the vascular system and washout from the tumor. There are several challenges associated with 
the self-healing materials based on DA reaction, such as the occurrence at high temperatures (80-120 °C) 
to trigger the rDA reaction that is not compatible with biological applications.[97,98]   
The drug release rate of our magnetic system is thermally on-demand controlled by switching on or off of 
HF-AMF. Upon AMF (frequency 1950 kHz, power 6200 W) the temperature of the sample increased from 
37 °C to 50 °C, and remained in this plateau for 15 min (Figure 4.26a). Figure 4.26b shows the cumulative 
release of DOX from functionalized CS-MNPs at 50 °C. The release profile shows more than 90% (after 15 
min) release of the DOX molecule. At elevated temperatures we note a reverse reaction and the 
reformation of maleimide and furan moieties respectively. With a fast heating rate of magnetic colloid 
upon AMF and a C=C bond/disbond thermally activated mechanism of functionalized nanoparticles, an 
accelerated drug release rate has been achieved. We observed a non-significant drug release at body 
temperature.   
The thermo-responsive release of the DOX from CS-MNPS was evaluated by varying the temperature of 
the samples (Figure 4.26c). At low temperature (25 °C) no release of doxorubicin was detected. A 
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significant DOX amount was released at 48 °C compared to 37 °C (40 % and 5 %, respectively). The higher 
release rate observed at elevated temperatures corresponds to an increased reverse rate in the rDA 
reaction.  
The release of DOX from functionalized CS-MNPs is on-demand controlled by switching on (i.e. 46 % 
release during a period of 4 min at 50 °C) or switching off the AMF as shown in Figure 4.26d.  
  
  
Figure 4.26. a) Time-dependent temperature curve of CS-MNPs under AMF. b) Cumulative DOX release profile 
under AMF. c) DOX release profile as a function of temperature. d) Switch-on under AMF and switch-off profile 
release of DOX. 
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confer thermo-tolerance as a result of continuous heat exposure within 30 min at 43 °C.[101] Inhibition of 
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MNPs. Otherwise, some authors indicated an uncoupling of thermo-tolerance and Hsp70 expression 
under slow rate heating conditions.[102] Magnetic hyperthermia is a viable tool for on-demand drug release 
inducing melting and subsequent capsule rupture on exposure via water ingress in vivo.[103] We report a 
novel magnetic drug release system that uses click chemistry reactions on-demand by heating upon AMF. 
A fast drug release is activated by rDA reaction and could be applied synergistically with hyperthermia. 
Other authors reported a new class of functionalized iron oxide nanoparticles initiating the rDA reaction 
at 70 °C without AMF.[104] Even though those temperatures seem to be very high for a biological medium, 
recent studies have shown the existence of local heating profiles generated at the magnetic nanoparticles 
surface upon AMF, leading to high temperatures within a contour only of a few nanometers.[105] Some 
authors use gold nano-rods to initiate the polyethylene glycol chain release through rDA by the photo-
thermal effect.[106] 
The stability of DOX loaded nanoparticles was evaluated up to 8 weeks in PBS at 25 °C (Figure 4.27). The 
results show that the stability of DOX loaded CS-MNPs was around 85 %. 
 
Figure 4.27. Stability of DOX loaded CS-MNPs in PBS up to 8 weeks. 
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4.4 PART IV 
This section concern the development of a dual pH- and thermo-responsive magnetic nanoparticles drug 
carrier by using the LBL technique which is suitable for the magneto-thermal therapy and controlled 
release. Spherical CS-MNPS with high magnetic responsiveness, synthesized by seed-mediated growth, 
were coated with PAH and PAA multilayers (Scheme 4.2). Subsequently, the release profile of the nano-
carriers was investigated via loading DOX molecules. The method uses the oscillating magnetic field as 
external trigger and the polyelectrolyte membrane as receptor. Due to the induced thermo-
responsiveness, the polymeric shell releases the entrapped drug by dissociation. The drug release rate is 
remotely controlled using on-off durations of oscillating magnetic field for a sustained drug release.  
 
 
Scheme 4.2. LBL assembly of CS-MNPs 
 
4.4.1 Structural characterizations of spherical magnetic nanoparticles 
The XRD pattern of the nanopowder is shown in Figure 4.28. The (220), (311), (400), (422), (511), and (440) 
diffraction peaks are matched to the Bragg reflections of the spinel ferrite structure. The mean crystallite 
size is 7.8±0.5 nm.   
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Figure 4.28. XRD pattern of CS-MNPs 
 
DLS was used to determine the mean hydrodynamic diameter of the particles (9.7±0.6 nm).  
XPS measurements were performed to examine the valence change of the cations and chemical 
composition of the CS-MNPs. Figure 4.29a shows the XPS photoemission peaks of O1s, Mn2p, Co2p, Zn2p, 
and fe2p core levels. The XPS of Co2p regions can be fitted into four contributions (Figure 4.29b). The XPS 
spectrum of Co2p exhibits two strong peaks located at BE of 781 and 796.4 eV, which can be attributed 
to Co2p3/2 and Co2p1/2, respectively, and are associated with corresponding shake ups peaks at 786.5 and 
802.7 eV, respectively. The Co2p spectrum indicate that Co exist in 2+ oxidation state, since the intense 
shakeup Co2p satellites are acquired from the unpaired valence 3d electron orbitals of the high spin 
Co2+.[64] In the Mn2p spectrum (Figure 4.29c), the major peak Mn2p3/2 is at 642.2 eV and the minor one 
Mn2p1/2 is at 653.8 eV, providing a clear evidence for Mn2+ chemical state on the sample surface.[65] The 
Mn2p3/2 spectra can be deconvoluted into three contributions centered at 640.4, 642.4, and 646.6 eV,  
which is in good agreement with the value reported for Mn2+, Mn4+, and its satellite, respectively.[66] The 
Fe2p spectra are characterized by BE of the Fe2p3/2 and Fe2p1/2 core levels of 711.2 and 724.3 eV, 
respectively (Figure 4.29d), and are accompanied by two corresponding satellite peaks for Fe2p3/2 and 
Fe2p1/2 visible at binding energies of around 719.2 and 731.0 eV, which is indicative of the presence of 
Fe3+ cations.[67] The binding energies of the Zn2p3/2 and Zn2p1/2 core level peaks are 1021.4 and 1044 eV, 
respectively, confirming the presence of Zn2+ species (Figure 4.29e).[91] The O1s peak is deconvoluted into 
two contributions at 530 and 531 eV, which are attributed to the crystal lattice oxygen and surface-
adsorbed oxygen, respectively (Figure 4.29f). 
20 30 40 50 60 70 80
-1000
0
1000
2000
3000
4000
5000
6000
7000
 
 
(5
3
3
)
(6
2
0
)
(4
4
0
)
(5
1
1
)
(4
2
2
)
(4
0
0
)
(3
1
1
)
(2
2
0
)
In
te
n
s
it
y
 (
a
.u
.)
2 (degrees)
59 
 
 
 
   
Figure 4.29. a) XPS spectra of CS-MNPs. Fitted photoelectron peaks of: b) Co2p1/2 and Co2p3/2; c) Mn2p1/2and 
Mn2p3/2; d) Fe2p1/2 and Fe2p3/2; e) Zn2p1/2 and Zn2p3/2; f) O1s. 
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4.4.2 Magnetic properties of spherical magnetic nanoparticles 
Magnetization analysis was carried out using a vibrating sample magnetometer in external magnetic fields 
ranging from -1 T to 1 T in order to study the static magnetic properties of CS-MNPs in powder form at 
room temperature. The magnetization curve of CS-MNPs, (PAH/PAA)-CS-MNPs (Sample S1), (PAH/PAA)2-
CS-MNPs (Sample S2), and (PAH/PAA)3-CS-MNPs (Sample S3) show a superparamagnetic behavior with a 
Ms of 45.6, 22.3, 18.7, and 13.1 emu/g, respectively (Figure 4.30).  
The lower value of Ms of coated CS-MNPs could be assigned to the coating of the surface layer that 
reduced the weight ratio of CS-MNPs in the sample. Superparamagnetic property and high SAR values are 
the key parameters for controlled drug release and synergistic hyperthermia. 
 
Figure 4.30. The magnetization curves of CS-MNPs and coated CS-MNPs. 
 
Figure 4.31a shows the temperature curves over time of CS-MNPs at different power values. In order to 
evaluate the heating performance on these CS-MNPs, the SAR value was measured. The sample was 
subjected to HF-AMF with different power values from 2500 to 5700 W at a frequency of 1950 kHz. SAR 
values expressed as W/g were calculated according to the equation (4.1). 
Figure 4.31b presents the variation of the SAR of the ferrofluid with the power of the HF-AMF. As 
expected, higher SAR values were recorded by increasing the applied power. In the case of CS-MNPs, the 
SAR values are (ranging from 200 to 360 W/g) higher compared to the core SAR values (ranging from 90 
to 170 W/g). This clearly indicates that the obtained Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 nanoparticles are 
magnetically exchange-coupled.  
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For superparamagnetic particles, the SAR will result from relaxation processes. These processes in 
ferrofluids are either due to reorientation of the magnetization within the particle (Néel losses) or due to 
reorientation of the particles and concomitant frictional losses (Brown losses).[107] In the case of systems 
with small dimensions of nanoparticles the contribution due to Brownian losses can be considered 
negligible. The SAR for superparamagnetic nanoparticles depends on the Néel losses.  
  
Figure 4.31. a) Temperature curves over time of CS-MNPs at different power values. b) The SAR functions of core 
and CS-MNPs. 
 
4.4.3 Cytotoxicity Assay of nanoparticles 
To evaluate the cytotoxicity of the core-shell magnetic nanoparticles, the functionalized CS-MNPs were 
incubated with HeLa, and Hep G2 cell lines and a standard MTT cell assay was used for the study. The cell 
viability of Hep G2 is decreased to 92 % after 24 h of treatment within the high-dosage concentrations of 
functionalized CS-MNPs (200 µg/mL) (Figure 4.32a); however, the cell viability of HeLa maintains around 
98 %, indicating that the functionalized CS-MNPs are nontoxic (Figure 4.32b). Therefore, the 
functionalized CS-MNPs can potentially be used as drug carriers in biological applications. 
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Figure 4.32. Cell viabilities of CS-MNPs with a) HeLa, and b) Hep G2 cells measured by MTT assay. 
 
4.4.4 Loading of doxorubicin with coated magnetic nanoparticles 
TEM images shows the shape and size of uncoated and coated MNPs (Figure 4.34). Figure 4.34a shows 
the DF-TEM of the CS-MNPs confirming the formation of CS-MNPs. The morphological change and the size 
enlargement are attributed to formation of the organic shell on the surface of the CS-MNPs, forming the 
encapsulation of the system into core-shell form. The thickness of the polyelectrolyte layer (S3) is 
estimated to be around of 6 nm.  
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Figure 4.33. a) TEM images of CS-MNPS dispersed in hexane. b) Dark field-TEM images of CS-MNPS. c) CS-MNPS 
coated with PAH as the first layer. d) CS-MNPS coated with PAA as the last layer, 6 layer coated. 
 
The change in the hydrodynamic size after each coating step was characterized by DLS (Figure 4.34 and 
Table 4.3). The mean hydrodynamic size of CS-MNPs dispersed in water is 55±2.3 nm. After first coating 
(PAH) on CS-MNPs, the particle diameter increased to 94±4.2 nm. 
 
 
Figure 4.34. DLS measurements of CS-MNPs and differently coated magnetic nanoparticles. 
 
Zeta potential measurement results show reversals of the surface charge of the MNPs upon each step of 
their coating (Figure 4.35 and Table 4.3). After positively charged PAH was coated onto the surface of the 
MNPs, the zeta potential and thus the total charge of the nanoparticles was changed from negative (-70 
mV) to positive (+55 mV), which indicates the coating of MNPs with the oppositely charged 
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polyelectrolytes. The loading of DOX did not affect the surface charge significantly. High Zeta potentials 
of the samples indicate the high dispersity and stability of the nanoparticles in the medium. 
 
Figure 4.35. Zeta potential measurements of differently coated magnetic nanoparticles. 
 
 
Table 4.3. DLS and Zeta potential result of uncoated magnetic nanoparticles and differently coated magnetic 
nanoparticles. 
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MNPs in Hexane 9.7±0.6  
MNPs-TMAOH 55±2.3 -70 
PAH-MNPs 94±4.2 +55 
(PAH/PAA)-MNPs 104±4.8 -50 
DOX-(PAH/PAA)-MNPs 115±3.9 -30 
PAH-(PAH/PAA)-MNPs 110±4.5 +52 
(PAH/PAA)2-MNPs 118±4.8 -45 
DOX-(PAH/PAA)2-MNPs 128±5.8 -25 
PAH-(PAH/PAA)2-MNPs 120±3.7 +43 
(PAH/PAA)3-MNPs 133±3.9 -44 
DOX-(PAH/PAA)3-MNPs 140±4.2 -22 
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The FTIR analyses were performed in order to reveal the coating on the MNPs and the loading of DOX. 
Figure 4.36 confirms the functional groups of the polyelectrolyte layer coatings of as-synthesized nano-
carriers. The spectrum of CS-MNPs shows the presence of Fe-O stretches at both the octahedral and 
tetrahedral sites. These can be seen in the large peaks around 580 and 620 cm-1, and also shows typical C-
H vibration in the wave length range of 2800-3000 cm -1. The typically vibrations in the wavelength range 
of 3000-3500 cm-1 could be attributed to the adsorbed water molecules on the nanoparticles surface. After 
first coating with PAH, the spectra confirmed the presence of the NH3 groups with stretching vibration band 
near 1500 cm-1 and 1600 cm-1. The characteristic vibrational bands include the symmetric and 
antisymmetric stretching frequencies of the carboxylate ion (COO-) at 1408 and 1562 cm-1, respectively, 
indicating the PAA layer formation. The significant peaks observed at 1555 cm-1 could be attributed to the 
N−H bending vibration of the −CO−NH− groups and confirmed the loading of DOX. 
 
Figure 4.36. FT-IR spectra of functionalized CS-MNPs. 
 
4.4.5 Doxorubicin release profile 
The desired anticancer drug (DOX) is attached to the last layer (PAA) of the coated CS-MNPs in the 
presence of the crosslinkers EDC and NHS for controlled release. The loading efficiency of DOX (90.5 %) 
on the coated CS-MNPs was obtained. The HF-AMF is used as an external on-off switching control to 
trigger the release of DOX from the coated CS-MNPs through magnetic heating.  
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The samples were placed inside a water-cooled copper coil producing an HF-AMF with the frequency of 
1950 kHz and a maximum power of 7200 W to measure the release of DOX considering parameters such 
as pH (5,7.2), buffer type (PBS), and temperature (25, 37, 40, 43 °C). At the on-off cycle, the sample was 
heated from 37 °C to 43 °C over the course of 3 min of pulsed duration with 7 min of cooling temperature 
profiles (Figure 4.37a). The results show that the DOX release from (PAH/PAA)-CS-MNPs (S1) is about 60 
% after 80 min of a single pulse of HF-AMF (Figure 4.37b). In contrast, when multiple on-off cycles were 
applied, approximately 40 % of the DOX was released from S1 in the first on-off cycles, while more DOX 
was released in a gradual response after subsequent on-off cycles up to 8 cycles (80 min; Figure 4.37c). A 
dramatic change in the amount of released drug is evident when applied to multiple on-off cycles. The 
drug release profiles of DOX show two stages: a burst release of DOX is obtained under HF-AMF within 
first 3 min followed by a slower rate of release.  
The coating thickness plays an important role in the elution of drug as it slows the dissociation of a drug 
from the coating and subsequently resulted in slower drug release rate. A similar on-off switchable drug 
release behavior was also observed for S2 and S3 (Figure 4.37c). The result show that the DOX was 
released from S2 within 110 min of subsequent on-off cycles, while DOX was released slower from S3 after 
subsequent on-off cycles of 140 min.  
This system can control the amount of drug release after the burst release of the first on-off cycle as a 
function of the duration of the magnetic pulse. The amount of DOX released over each on-off cycle varies 
directly with the duration of magnetic pulse. Thus, drug release could be controlled by modulating both 
the frequency and duration of magnetic pulse. Other authors reported a DOX release from functionalized 
core/shell magnetic nanoparticles at 37 °C without controlling the rate of released DOX.[108] 
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Figure 4.37. a) HF-AMF triggered release of DOX loaded coated CS-MNPs in on-off cycles profiles. b) Fluorescence 
intensity profiles upon the application of HF-AMF after 80 min in multiple pulses and in a single pulse. c) DOX 
release profiles upon the application of HF-AMF 
 
Studies on the pH and temperature induced release of DOX were carried out. The extent of DOX release 
from the sample in the PBS (pH 5.0) is higher than the ones with pH of 7.4 (Figure 4.38a).  The 100 min 
cumulative release in pH 7.4 media is about 40 %, whereas that in pH 5.0 media is about 100%, which 
indicates that the low pH helps to accelerate the release of DOX at tumor cell.  
Cumulative DOX release as a function of time with application of an HF-AMF but at different temperatures, 
i.e. 25 °C, 37 °C, 40 °C, and 43 °C, in PBS at pH 5 are represented in Figure 4.38b. The amount of DOX 
released was 43 % at 25 °C due to the hydrolysis kinetic of the layer at acidic pH. On the other hand 65 % 
of DOX release was observed at 37 °C. After reaching the temperature to 40 °C, the DOX release was 
strongly enhanced and increased to 77 %. The maximal release of DOX was found at 43 °C.  Acidic pH 
facilitates the release of the drug by promoting the dissociation of the layer adjacent to the heat 
generated by CS-MNPs after subjected to HF-AMF, which accelerate the rate of the hydrolysis reaction 
and induce the thermo-responsiveness of the polymer. Thus, by combining both changes of the pH and 
higher temperature, a controlled release of the DOX can be obtained. 
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Figure 4.38. a) Cumulative release of DOX upon the application of HF-AMF at different pH for DOX loaded coated 
CS-MNPs. b) Cumulative DOX release profile as a function of temperature at acidic pH. 
 
 
Pulsatile drug delivery systems have attracted attraction because of their multiple advantages over 
conventional dosage forms. They deliver the drug at the selective time, at the selective site of action and 
in the right amount, which provides more benefit and increased patient compliance. The drug is released 
slowly and completely as a pulse after a lag time. These products follow the sigmoid release profile 
characterized by a time period. They reduce the dose frequency, and cost, which reduces the side effects, 
and thus improving patient compliance.  
Some authors developed magnetic hydrogel nanocomposites for remote controlled pulsatile drug 
release.[109] Nanocomposites were synthesized by incorporation of superparamagnetic Fe3O4 particles in 
negative temperature sensitive poly (N-isopropylacrylamide) hydrogels. Other authors use a high-
frequency magnetic field to control the pulsatile release of vitamin B12 from a ferrogel.[110] Other Using 
Magnetic Implants for local drug delivery which provide a pulsatile release of the drug.[111] Katono et al. 
developed an interpenetrating polymer networks composed of polyacrylic acid and poly(acrylamide-co-
butyl methacrylate), that showed a positive thermosensitvity.[112] The swelling of these hydrogel was 
reversible, responding to the temperature changes. Ilmain et al. reported an interpenetrating network of 
polyacrylic acid and polyacrylamide that swell above their UCST, due to hydrogen bond between the two 
different networks.[113] Shin et al. designed a temperature- and pH-responsive drug delivery system by 
using interpenetrating polymer network hydrogels constructed with polyacrylic acid and polyvinyl 
alcohol.[114] 
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5 SUMMARY AND CONCLUSION 
A multi-perspective investigation, including (i) the selection of MNPs to meet the individual needs of 
future biomedical applications, (ii) the effect of experimental parameters on the behavior of MNPs, (iii) 
the functionalization of MNPs and (iv) the drug release investigation, has been carried out in this work. 
The first part covered general considerations concerning the synthesis of CS-MNPs. It showed how the 
unique physical and magnetic properties of the CS-MNPs can be specifically tuned by variation of the zinc 
substitution. The morphology, crystal structure and magnetic properties of the ZnxCo1-xFe2O4@MnFe2O4 
have been investigated. The formation of ZnxCo1-xFe2O4@MnFe2O4 was confirmed by the XRD technique, 
and TEM. XPS measurements showed the elements distribution, homogeneity, and formation of 
core/shell of the as prepared samples. The lattice constant, ionic radii, and crystallite size were found to 
increase with the increase in zinc concentration. The Ms and SAR was found to increase with the increase 
in zinc substitution (x=0.4) and can be explained in terms of the cation distribution between the 
tetrahedral and octahedral sites of the spinel structure of the core. Low Hc was observed for the higher 
Zn concentration for the nanoparticles. The nano-crystallinity and high SAR values of the magnetic 
nanoparticles suggest it can be used for many practical applications such as magnetic drug delivery, 
hyperthermia and MRI. 
The second part of this thesis covered the structural and magnetic properties of Zn0.4Co0.6Fe2O4@ 
Zn0.4Mn0.6Fe2O4 which can be tailored by the precursor concentration and reaction time. The particle size 
can easily be controlled by adjusting the reaction time, precursor concentration, and the heating rate. It 
was demonstrated that the particle size increased with reaction time. The impact of the core/shell 
Zn0.4Co0.6Fe2O4@ Zn0.4Mn0.6Fe2O4 exchange interaction on the specific absorption rate has been 
investigated. Core/shell exchange coupling leads to an increase of the specific absorption rate. Also the 
concentration of the precursor and the synthesis time had comparatively effects on the magnetic heating 
power. We suggest that the present work might be helpful for the design of core/shell particles for a 
variety of systems that depend on heat induction, including magnetic hyperthermia therapy and drug 
delivery system. This study is also needed for the proper design of the material based on a choice of the 
features to be tuned. 
In part 3 a novel magnetic drug release system that uses click chemistry reactions on-demand by heating 
upon AMF has been reported. Our synthetic design, which is based on a different multifunctionalization 
of CS-MNPs, thus controls the release of the DOX whilst maintaining the colloidal stability and magnetic 
properties of the CS-MNPs. A fast drug release is activated by rDA reaction and could be applied 
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synergistically with hyperthermia. At body temperature the amount of released drug is hardly detectable, 
thus minimizing the adverse effects of anti-cancer drug. Exposure of the system to several distinct 
temperatures demonstrated a strongly temperature-dependent release of the DOX from the nano-
carriers, supporting a DA/rDA mechanism. The drug release rate is controlled by switching “off” or “on” 
the AMF without significant heating of the medium. High sensitivity and excellent biocompatibility of our 
versatile system yield an improved efficacy of a medical treatment as outlined above and allow to design 
of remotely controllable highly functional nano-systems.  
In contrast of the rDA activated rapid release system, the part 4 concerned the development of a pH and 
magnetic dual-responsive drug delivery system, consists of functionalized core/shell bi-magnetic 
nanoparticles, which – via a layer-by-layer technique – are coated by multiple polyelectrolytes and 
functionalized with the chemotherapeutics doxorubicin. We expect that a rapid heat generation of CS-
MNPs will induce cell necrosis suppressing the development of MDR and thermo-tolerance (e.g. heat 
shock protein) that usually is associated with slow heating rate. Improved DOX release was observed at 
acidic environment (pH 5.0) and at higher temperature (43 °C). This behavior approved the multiple 
stimuli responsive of the nano-carrier. On-off switch controlled release could be successfully tuned 
through adjustment of the number of layers and the applying magnetic field. Following DLS, Zeta potential 
and TEM analysis, it was found that the system was highly dispersed and stable in the medium. The system 
displayed good cytocompatibility, superparamagnetism, and thermosensitivity. The system exhibited a 
good therapeutic efficacy by providing repeated, long-term, on demand drug delivery for a variety of 
medical application, thus enhancing the therapeutic efficacy of the drug. Such a novel magnetic drug 
delivery system makes the functionalized CS-MNPs suitable for cancer treatment. 
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APPENDIX 
 
A1. CHEMICALS 
Description CAS No. Supplier 
Zinc acetylacetonate hydrate 108503-47-5 Sigma-Aldrich 
Cobalt (II) acetylacteonate  14024-48-7 Sigma-Aldrich 
Iron (III) acetylacetonate 14024-18-1 ACROS Organics 
Manganese (II) acetylacteonate 14024-58-9 Sigma-Aldrich 
Tetramethylammonium hydroxide solution 75-59-2 Sigma-Aldrich 
Alendronic acid 121268-17-5 Santa Cruz Biotechnology 
Oleic acid 112-80-1 Sigma-Aldrich 
oleylamine 112-90-3 Sigma-Aldrich 
1,2-Hexadecanediol 6920-24-7 Sigma-Aldrich 
benzyl ether 103-50-4 Sigma-Aldrich 
N-(2-carboxyethyl)maleimide 7423-55-4 Sigma-Aldrich 
2-furfuryl isothiocyanate 4650-60-6 Fluka 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride 
25952-53-8 Fluka 
N-hydroxysuccinimide 6066-82-6 Sigma-Aldrich 
doxorubicin hydrochloride 25316-40-9 Sigma-Aldrich 
Poly(acrylic acid) 9003-01-4 Sigma-Aldrich 
Poly(allylamine hydrochloride) 71550-12-4 Sigma-Aldrich 
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A2. LIST OF ABBREVIATIONS 
Magnetic nanoparticles  MNPs 
Core/shell magnetic nanoparticles  CS-MNPs 
Specific absorption rate  SAR 
Doxorubicin  DOX 
High-frequency alternating magnetic field  HF-AMF 
Alternating magnetic field  AMF 
Retro Diels/Alder reaction  rDA 
Diels/Alder reaction  DA 
Layer-by-layer  LBL 
Poly(allylamine-hydrochloride)  PAH 
polyacrylic acid  PAA 
Magnetic resonance imaging  MRI 
Reference  ref 
Ferromagnet  FM 
Antiferromagnet  AFM 
Minute  min 
Hour  h 
Second  sec 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride  EDC 
N-Hydroxysuccinimide  NHS 
X-ray diffraction  XRD 
Transmission electron microscopy  TEM 
Dark-field Transmission electron microscopy  DF-TEM 
X-ray photoelectron spectroscopy  XPS 
Dynamic light scattering  DLS 
Fourier transform infrared spectroscopy  FT-IR 
Thermogravimetry  TG  
Vibrating sample magnetometery  VSM 
Saturation magnetization  Ms 
Remanence magnetization  Mr 
Coercivity  Hc 
Curie temperature  Tc 
Binding energy  BE 
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A3. PUBLICATIONS 
A3.1 Journal article 
M. Hammad, V. Nica, R. Hempelmann  
On-Command Controlled Drug Release by Diels-Alder Reaction Using Bi-Magnetic Core/Shell Nano-
carriers. (Submitted to Colloids and Surfaces B: Biointerfaces) 
 
M. Hammad, V. Nica, R. Hempelmann  
On-Off Switch Controlled Doxorubicin Release from Thermo- and pH-Responsive Coated Bi-Magnetic 
Nano-Carriers. (Submitted to Journal of Nanoparticles Research) 
 
M. Hammad, V. Nica, R. Hempelmann  
Synthesis and characterization of bi-magnetic core/shell for hyperthermia applications. (Submitted to IEEE 
Transactions on Magnetics) 
 
M. Hammad, V. Nica, R. Hempelmann  
Enhanced Specific Absorption Rate of Bi-magnetic Nanoparticles for Heating Applications. (In preparation) 
 
A3.2 Conference proceedings 
M. Hammad and R. Hempelmann 
Functionalization of Magnetic Nanoparticles by Diels-Alder Reaction. 
15th German Ferrofluid Workshop, 15 - 17 July 2015, Rostock, Germany. 
 
V. Nica, M. Hammad, M.L. Garcia Martin, R. Hempelmann 
Shape Anisotropic Bi-magnetic Nanoparticles for Application in Hyperthermia. 
TIM15-16 Physics Conference, 26 - 28 May 2016, Timisoara, Romania. 
 
M. Hammad, V. Nica, and R. Hempelmann 
Synthesis and Characterization of Bi-magnetic Core/Shell for Hyperthermia Applications. 
11th European Magnetic Sensors and Actuators, 12 - 15 July 2016, Torino, Italy. 
V. Nica, M. Hammad, M.L. Garcia Martin, R. Hempelmann 
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Influence of the Surfactants on the Physiochemical Properties of Hard/Soft Bi-magnetic Nanoparticles. 
11th European Magnetic Sensors and Actuators, 12 - 15 July 2016, Torino, Italy. 
 
V. Nica, M. Hammad, M.L. Garcia Martin, R. Hempelmann 
On-Command Multifunctional Bi-magnetic Core-Shell Nanoparticles for Biomedical Applications 
Advances in Functional Materials (AFM 2016), 8 - 11 Augst 2016, Jeju, South Korea 
 
V. Nica, M. Hammad, M.L. Garcia Martin, R. Hempelmann 
Enhanced Specific Absorbtion Rate of Exchange Coupled Bi-Magnetic Nanoparticles for High Frequency 
Electromagnetic Absorption 
Europe-Korea Conference on Science and Technology (EKC 2016), 27 - 30 July 2016, Berlin, Germany 
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